WO2014139884A2 - Cibles et composés moléculaires destinés au traitement de la fibrose, et méthodes utilisées pour les identifier - Google Patents
Cibles et composés moléculaires destinés au traitement de la fibrose, et méthodes utilisées pour les identifier Download PDFInfo
- Publication number
- WO2014139884A2 WO2014139884A2 PCT/EP2014/054442 EP2014054442W WO2014139884A2 WO 2014139884 A2 WO2014139884 A2 WO 2014139884A2 EP 2014054442 W EP2014054442 W EP 2014054442W WO 2014139884 A2 WO2014139884 A2 WO 2014139884A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- fibrosis
- differentiation
- fibroblast
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 200
- 238000011282 treatment Methods 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title claims description 166
- 206010016654 Fibrosis Diseases 0.000 title claims description 92
- 230000004761 fibrosis Effects 0.000 title claims description 84
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 179
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 173
- 229920001184 polypeptide Polymers 0.000 claims abstract description 164
- 230000004069 differentiation Effects 0.000 claims abstract description 119
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 110
- 230000019305 fibroblast migration Effects 0.000 claims abstract description 100
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 66
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 66
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 64
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 56
- 230000005764 inhibitory process Effects 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 169
- 230000014509 gene expression Effects 0.000 claims description 113
- 210000002950 fibroblast Anatomy 0.000 claims description 101
- 239000004055 small Interfering RNA Substances 0.000 claims description 98
- 230000000694 effects Effects 0.000 claims description 78
- 102000040430 polynucleotide Human genes 0.000 claims description 77
- 108091033319 polynucleotide Proteins 0.000 claims description 77
- 239000002157 polynucleotide Substances 0.000 claims description 64
- 230000002401 inhibitory effect Effects 0.000 claims description 52
- 238000012360 testing method Methods 0.000 claims description 52
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 50
- 230000027455 binding Effects 0.000 claims description 48
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 47
- 230000000692 anti-sense effect Effects 0.000 claims description 45
- -1 CCL22 Proteins 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 35
- 108090000994 Catalytic RNA Proteins 0.000 claims description 32
- 102000053642 Catalytic RNA Human genes 0.000 claims description 32
- 108091092562 ribozyme Proteins 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 32
- 239000002679 microRNA Substances 0.000 claims description 31
- 208000027418 Wounds and injury Diseases 0.000 claims description 30
- 230000001960 triggered effect Effects 0.000 claims description 30
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 230000000295 complement effect Effects 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 230000003612 virological effect Effects 0.000 claims description 24
- 241000282414 Homo sapiens Species 0.000 claims description 23
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 22
- 206010052428 Wound Diseases 0.000 claims description 22
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 22
- 210000004072 lung Anatomy 0.000 claims description 22
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 20
- 230000037390 scarring Effects 0.000 claims description 20
- 206010039710 Scleroderma Diseases 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 210000000651 myofibroblast Anatomy 0.000 claims description 18
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 16
- 108700011259 MicroRNAs Proteins 0.000 claims description 16
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 16
- 108010006654 Bleomycin Proteins 0.000 claims description 15
- 229960001561 bleomycin Drugs 0.000 claims description 15
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 238000013508 migration Methods 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000005012 migration Effects 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 108010085238 Actins Proteins 0.000 claims description 11
- 108010081589 Becaplermin Proteins 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 102000007469 Actins Human genes 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 231100000331 toxic Toxicity 0.000 claims description 10
- 230000002588 toxic effect Effects 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 230000007613 environmental effect Effects 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
- 208000024985 Alport syndrome Diseases 0.000 claims description 8
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 8
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 8
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 8
- 206010018691 Granuloma Diseases 0.000 claims description 8
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 8
- 208000018565 Hemochromatosis Diseases 0.000 claims description 8
- 208000028782 Hereditary disease Diseases 0.000 claims description 8
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 claims description 8
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 8
- 206010021263 IgA nephropathy Diseases 0.000 claims description 8
- 208000002260 Keloid Diseases 0.000 claims description 8
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 8
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 8
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 8
- 208000004362 Penile Induration Diseases 0.000 claims description 8
- 208000020758 Peyronie disease Diseases 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 8
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 8
- 108091081021 Sense strand Proteins 0.000 claims description 8
- 201000010001 Silicosis Diseases 0.000 claims description 8
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 8
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 8
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 239000010425 asbestos Substances 0.000 claims description 8
- 208000023819 chronic asthma Diseases 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 8
- 208000003215 hereditary nephritis Diseases 0.000 claims description 8
- 230000009610 hypersensitivity Effects 0.000 claims description 8
- 230000001969 hypertrophic effect Effects 0.000 claims description 8
- 230000000642 iatrogenic effect Effects 0.000 claims description 8
- 210000001117 keloid Anatomy 0.000 claims description 8
- 206010028537 myelofibrosis Diseases 0.000 claims description 8
- 201000004931 neurofibromatosis Diseases 0.000 claims description 8
- 208000037803 restenosis Diseases 0.000 claims description 8
- 229910052895 riebeckite Inorganic materials 0.000 claims description 8
- 201000000306 sarcoidosis Diseases 0.000 claims description 8
- 208000020431 spinal cord injury Diseases 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 7
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 5
- 102100031168 CCN family member 2 Human genes 0.000 claims description 5
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 239000002356 single layer Substances 0.000 claims description 5
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims description 4
- 210000002460 smooth muscle Anatomy 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 claims description 2
- 102100023701 C-C motif chemokine 18 Human genes 0.000 claims description 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 2
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 2
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims description 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 2
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 claims description 2
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 claims description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 2
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 claims description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 2
- 102100026236 Interleukin-8 Human genes 0.000 claims description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 58
- 201000010099 disease Diseases 0.000 abstract description 53
- 108090000623 proteins and genes Proteins 0.000 description 66
- 239000013642 negative control Substances 0.000 description 43
- 239000013641 positive control Substances 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108020004999 messenger RNA Proteins 0.000 description 31
- 241000700605 Viruses Species 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 108091034117 Oligonucleotide Proteins 0.000 description 26
- 238000005259 measurement Methods 0.000 description 23
- 230000008569 process Effects 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 239000000523 sample Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 108091070501 miRNA Proteins 0.000 description 16
- 230000009368 gene silencing by RNA Effects 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 229940000406 drug candidate Drugs 0.000 description 12
- 102000009618 Transforming Growth Factors Human genes 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000011218 segmentation Effects 0.000 description 11
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 10
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 108090000862 Ion Channels Proteins 0.000 description 9
- 102000004310 Ion Channels Human genes 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000007405 data analysis Methods 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000010361 transduction Methods 0.000 description 9
- 230000026683 transduction Effects 0.000 description 9
- 230000007704 transition Effects 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101000709006 Homo sapiens Rhomboid-related protein 2 Proteins 0.000 description 7
- 102100032686 Rhomboid-related protein 2 Human genes 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000007423 screening assay Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 229920000954 Polyglycolide Polymers 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000004633 polyglycolic acid Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000006748 scratching Methods 0.000 description 6
- 230000002393 scratching effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 5
- 238000000116 DAPI staining Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000692650 Homo sapiens Prostacyclin receptor Proteins 0.000 description 5
- 101000863845 Homo sapiens Sedoheptulokinase Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 102100026476 Prostacyclin receptor Human genes 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 102100029990 Sedoheptulokinase Human genes 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 206010015719 Exsanguination Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 229940095074 cyclic amp Drugs 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011311 validation assay Methods 0.000 description 4
- 238000012049 whole transcriptome sequencing Methods 0.000 description 4
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 3
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 101710145505 Fiber protein Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 3
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- PKUWKAXTAVNIJR-UHFFFAOYSA-N O,O-diethyl hydrogen thiophosphate Chemical compound CCOP(O)(=S)OCC PKUWKAXTAVNIJR-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 208000004608 Ureteral Obstruction Diseases 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 229940124452 immunizing agent Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000013059 nephrectomy Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 101000997963 Aequorea victoria Green fluorescent protein Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001129833 Homo sapiens Protein-L-isoaspartate(D-aspartate) O-methyltransferase Proteins 0.000 description 2
- 101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100031674 Protein-L-isoaspartate(D-aspartate) O-methyltransferase Human genes 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 210000000630 fibrocyte Anatomy 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000003709 image segmentation Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000009752 translational inhibition Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 238000002759 z-score normalization Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100034156 Apical endosomal glycoprotein Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091009167 Bloom syndrome protein Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000007809 Boyden Chamber assay Methods 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000014837 CACNA1G Human genes 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102100023243 Calcium-activated potassium channel subunit beta-3 Human genes 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108091027874 Group I catalytic intron Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 101000780564 Homo sapiens Apical endosomal glycoprotein Proteins 0.000 description 1
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001049846 Homo sapiens Calcium-activated potassium channel subunit beta-3 Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000981500 Homo sapiens Pantothenate kinase 3 Proteins 0.000 description 1
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
- 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100024126 Pantothenate kinase 3 Human genes 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000713896 Spleen necrosis virus Species 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O bleomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 230000019113 chromatin silencing Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- OQIHDECISCAIPH-UHFFFAOYSA-N dihydroxy-(2-methoxyethylperoxy)-sulfanylidene-lambda5-phosphane Chemical class COCCOOP(O)(O)=S OQIHDECISCAIPH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000012729 kappa analysis Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000013442 quality metrics Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/01—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with NAD+ or NADP+ as acceptor (1.7.1)
- C12Y107/01007—GMP reductase (1.7.1.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01077—Protein-L-isoaspartate(D-aspartate) O-methyltransferase (2.1.1.77)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01014—Sedoheptulokinase (2.7.1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01033—Pantothenate kinase (2.7.1.33)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
- C12Y207/04006—Nucleoside-diphosphate kinase (2.7.4.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
- C12Y207/08002—Diacylglycerol cholinephosphotransferase (2.7.8.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/088—Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Definitions
- the present invention is in the field of molecular biology and biochemistry.
- the present invention relates to methods for identifying agents useful in treatment of fibrotic disease, in particular, agents that inhibit fibroblast migration and differentiation. Inhibition of fibroblast migration and differentiation is useful in the prevention and / or treatment of fibrotic conditions and other diseases where processes of fibroblast migration and differentiation play role.
- the present invention provides methods for identifying agents for use in the prevention and / or treatment of fibrotic diseases.
- Fibrosis is characterized by excessive deposition of scar tissue. Fibrosis is one of the largest groups of diseases for which there is no therapy. Fibrosis is responsible for morbidity and mortality associated with organ failure in a variety of chronic diseases affecting the lungs, heart, kidneys, liver and skin. It has been estimated that nearly 45% of all deaths in the developed world are caused by fibrotic conditions which include: cardiovascular disease, pulmonary fibrosis, diabetic nephropathy and liver cirrhosis (Wynn, 2004).
- Fibrosis and especially idiopathic pulmonary fibrosis, is a disease that is receiving increasing attention. Unfortunately, little is known about the pathogenesis of fibrosis and only recently the various cellular and molecular processes that contribute to this disease have been unveiled. The overall consensus is that fibrosis is a result of an imbalance in the immune and repair response following infection and/or tissue damage (reviewed by Lekkerkerker et al, 2012)These responses are the result of an intricate interplay between various cell types such as epithelial cells, fibroblasts, macrophages, fibrocytes, smooth muscle cells and endothelial cells. An imbalance in the activity in one or more of these cell types is expected to contribute to fibrosis.
- fibrotic diseases A common theme of fibrotic diseases is the abnormal persistence of a particular specialized form of fibroblast, termed the myofibroblast (Gabbiani, 2003; Wynn, 2008).
- myofibroblast Gabbiani, 2003; Wynn, 2008.
- ECM extra-cellular matrix
- fibroblasts differentiate into a myofibroblast phenotype, characterized by expression of a- smooth muscle actin (aSMA), secretion of collagen type I and III and increased migration and contractility (Wynn, 2007).
- SMA smooth muscle actin
- fibronectin fibronectin, collagen, and/or laminin
- fibroblasts have been put forward including proliferation of resident fibroblasts, generation of fibroblasts from epithelial cells through epithelial mesenchymal transition (EMT), differentiation of circulating fibrocytes or mesenchymal progenitor cells.
- EMT epithelial mesenchymal transition
- fibroblasts are the major contributor to the pool of myofibroblasts in fibrogenic foci (Lekkerkerker et al, 2012). A prerequisite for this contribution is the migration of fibroblasts towards foci and subsequent expansion and differentiation. Many factors have been identified over the years that activate the fibroblast and thereby enhance their migratory and/or proliferative capacity. These include growth factors PDGF, CTGF and TGFB, but also chemokines such as CCL11 (Puxeddu et al, 2006), CCL21 (Pierce et al, 2007), CCL24 and CCL26 (Kohan et al, 2010).
- TGFB is a pleiotropic cytokine that has many versatile effects on the fibrogenic process in the lung, including but not restricted to the already discussed potentiation of EMT.
- TGFB isoforms have also been shown to regulate deposition of many components of the ECM components (Eickelberg et al, 1999) and affect the migratory and differentiation potential of fibroblasts towards myofibroblasts (Scotton et al, 2007).
- PDGF vascular endothelial growth factor
- the present invention is based on the discovery that agents that inhibit the expression and / or activity of the TARGETS disclosed herein are capable of inhibiting the differentiation and migration of fibroblasts as indicated by a inhibition of fibroblast migration and the inhibition of the expression and/or release of markers of fibroblast differentiation into myofibroblasts, in particular a suppression of the release or expression of a-smooth muscle actin.
- the present invention therefore, provides TARGETS which play a role in fibroblast migration and differentiation, methods for screening for agents capable of down-regulating the expression and / or activity of TARGETS and the use of these agents in the prevention and / or treatment of fibrotic diseases, in particular diseases associated with fibroblast migration and differentiation.
- the present invention provides TARGETS which are involved in the differentiation and biology of fibroblasts, in particular with fibrotic diseases. In a particular aspect, the present invention provides TARGETS which are involved in or otherwise associated with development of fibrotic diseases.
- the present invention relates to a method for identifying a compound useful for the treatment of fibrosis, said method comprising: contacting a test compound with a TARGET polypeptide, fragments and functional derivatives thereof, determining a binding affinity of the test compound to said polypeptide or an activity of said polypeptide, contacting the test compound with a population of fibroblasts, measuring a property related to fibroblast migration or differentiation, and identifying a compound capable of inhibiting fibroblast migration or differentiation and which either demonstrates a binding affinity to said polypeptide or is able to inhibit the activity of said polypeptide.
- the present invention further relates to a method for identifying a compound useful for the treatment of fibrosis, said method comprising: contacting a test compound with population of fibroblasts and expressing a TARGET polypeptide, measuring expression and/or amount of said polypeptide in said cells, measuring a property related to fibroblast migration or differentiation, and identifying a compound which reduces the expression and/or amount of said polypeptide and which is capable of inhibiting fibroblast migration or differentiation.
- the present invention further relates to a method for identifying a compound that inhibits fibroblast migration and differentiation, said method comprising: contacting a test compound with population of fibroblasts and expressing a TARGET polypeptide, measuring expression and/or amount of said polypeptide in said cells, measuring a property related to fibroblast migration or differentiation, and identifying a compound which reduces the expression and/or amount of said polypeptide and which is capable of inhibiting fibroblast migration or differentiation.
- the present invention provides a method for identifying a compound that inhibits fibroblast migration and differentiation said method comprising: contacting a test compound with a TARGET polypeptide, fragments or structurally functional derivatives thereof, determining a binding affinity of the test compound to said polypeptide or expression or an activity of said polypeptide, and identifying a compound fibroblast migration and differentiation as a compound which demonstrates a binding affinity to said polypeptide and/or is able to inhibit the expression or activity of said polypeptide.
- the present invention also relates to:
- compositions comprising an antibody or a fragment thereof which specifically binds to a TARGET polypeptide, for use in the treatment of a fibrotic condition.
- compositions comprising an agent selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), mirroRNA (miRNA) and a short-hairpin RNA (shRNA) for use in the treatment of a fibrotic condition, wherein said agent comprises a nucleic acid sequence complementary to, or engineered from, a naturally- occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid sequence selected encoding a TARGET polypeptide for use in the treatment of a fibrotic condition.
- an agent selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), mirroRNA (miRNA) and a short-hairpin RNA (shRNA) for use in the treatment of a fibrotic condition
- said agent comprises a nucleic acid sequence complementary
- Another aspect of this invention relates to an in vitro method of inhibiting fibroblast migration and differentiation, said method comprising contacting a population of fibroblasts with an inhibitor of an activity or expression of a TARGET polypeptide.
- Figure 1 shows principles of image segmentation based on phalloidin staining and DAPI staining of nuclei.
- Figure 2 outlines the assay set-up of the fibroblast scratch assay.
- Figure 3 shows dot plots of rescreen data. Controls and samples data are presented after normalizing the data using robust Z-score.
- Figure 4 shows image segmentation principles based on DAPI staining of nuclei and aSMA staining of cells either non-triggered or triggered with TGFB.
- Figure 5 outlines the assay setup of the fibroblast-to-myofibroblast transition (FMT) assay.
- FMT fibroblast-to-myofibroblast transition
- Figure 6 shows dot plots of controls and samples based Robust Z-Score normalization in FMT assay.
- Figure 7 shows dot plots of controls and samples after Robust Z-Score normalization based on negative controls in the "on target” assay.
- FIG. 8 shows a schematic overview of the CellTiter Blue (CTB) toxicity assay.
- agent means any molecule, including polypeptides, polynucleotides, natural products and small molecules.
- agent includes compounds such as test compounds or drug candidate compounds.
- the term 'activity inhibitory agent' or 'activity inhibiting agent' means an agent, e.g. a polypeptide, small molecule, compound designed to interfere or capable of interfering selectively with the activity of a specific polypeptide or protein normally expressed within or by a cell.
- the term 'agonist' refers to an agent that stimulates the receptor the agent binds to in the broadest sense.
- the term 'antagonist' is used to describe an agent that does not provoke a biological response itself upon binding to a receptor, but blocks or dampens agonist-mediated responses, or prevents or reduces agonist binding and, thereby, agonist-mediated responses.
- the term 'assay' means any process used to measure a specific property of an agent, including a compound.
- a 'screening assay' means a process used to characterize or select compounds based upon their activity from a collection of compounds.
- binding affinity' is a property that describes how strongly two or more compounds associate with each other in a non-covalent relationship. Binding affinities can be characterized qualitatively, (such as 'strong', 'weak', 'high', or 'low') or quantitatively (such as measuring the KD).
- the term 'carrier' means a non-toxic material used in the formulation of pharmaceutical compositions to provide a medium, bulk and/or useable form to a pharmaceutical composition.
- a carrier may comprise one or more of such materials such as an excipient, stabilizer, or an aqueous pH buffered solution.
- physiologically acceptable carriers include aqueous or solid buffer ingredients including phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®.
- aqueous or solid buffer ingredients including phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide
- the term 'complex' means the entity created when two or more compounds bind to, contact, or associate with each other.
- the term 'compound' is used herein in the context of a 'test compound' or a 'drug candidate compound' described in connection with the assays of the present invention.
- these compounds comprise organic or inorganic compounds, derived synthetically or from natural sources.
- the compounds include inorganic or organic compounds such as polynucleotides (e.g. siRNA or cDNA), lipids or hormone analogs.
- Other biopolymeric organic test compounds include peptides comprising from about 2 to about 40 amino acids and larger polypeptides comprising from about 40 to about 500 amino acids, including polypeptide ligands, enzymes, receptors, channels, antibodies or antibody conjugates.
- the term 'condition' or 'disease' means the overt presentation of symptoms (i.e., illness) or the manifestation of abnormal clinical indicators (for example, biochemical indicators). Alternatively, the term 'disease' refers to a genetic or environmental risk of or propensity for developing such symptoms or abnormal clinical indicators. [0036]
- the term 'contact' or 'contacting' means bringing at least two moieties together, whether in an in vitro system or an in vivo system.
- polypeptide' relates to those peptides, oligopeptides, polypeptides, proteins and enzymes that comprise a stretch of contiguous amino acid residues of the polypeptide and that retain a biological activity of the protein, for example, polypeptides that have amino acid mutations compared to the amino acid sequence of a naturally- occurring form of the polypeptide.
- a derivative may further comprise additional naturally occurring, altered, glycosylated, acylated or non- naturally occurring amino acid residues compared to the amino acid sequence of a naturally occurring form of the polypeptide.
- It may also contain one or more non-amino acid substituents, or heterologous amino acid substituents, compared to the amino acid sequence of a naturally occurring form of the polypeptide, for example a reporter molecule or other ligand, covalently or non-covalently bound to the amino acid sequence.
- the term 'derivatives of a polynucleotide' relates to DNA-molecules, RNA-molecules, and oligonucleotides that comprise a stretch of nucleic acid residues of the polynucleotide, for example, polynucleotides that may have nucleic acid mutations as compared to the nucleic acid sequence of a naturally occurring form of the polynucleotide.
- a derivative may further comprise nucleic acids with modified backbones such as PNA, polysiloxane, and 2'-0-(2-methoxy) ethyl-phosphorothioate, non- naturally occurring nucleic acid residues, or one or more nucleic acid substituents, such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl-, chloro-, and methanocarbanucleosides, or a reporter molecule to facilitate its detection.
- nucleic acids with modified backbones such as PNA, polysiloxane, and 2'-0-(2-methoxy) ethyl-phosphorothioate, non- naturally occurring nucleic acid residues, or one or more nucleic acid substituents, such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl-, chloro-, and methanocarbanu
- the term 'endogenous' shall mean a material that a mammal naturally produces. Endogenous in reference to the term 'enzyme', 'protease', 'kinase', or G-Protein Coupled Receptor ('GPCR') shall mean that which is naturally produced by a mammal (for example, and not by limitation, a human). In contrast, the term non- endogenous in this context shall mean that which is not naturally produced by a mammal (for example, and not by limitation, a human). Both terms can be utilized to describe both in vivo and in vitro systems.
- the endogenous or non- endogenous TARGET may be in reference to an in vitro screening system.
- screening of a candidate compound by means of an in vivo system is feasible.
- the term 'expressible nucleic acid means a nucleic acid coding for or capable of encoding a proteinaceous molecule, peptide or polypeptide, and may include an RNA molecule, or a DNA molecule.
- the term ' expression' comprises both endogenous expression and non- endogenous expression, including overexpression by transduction.
- 'expression inhibitory agent' or 'expression inhibiting agent' means an agent, e.g. a polynucleotide designed to interfere or capable of interfering selectively with the transcription, translation and/or expression of a specific polypeptide or protein normally expressed within or by a cell. More particularly and by example, 'expression inhibitory agent' comprises a DNA or RNA molecule that contains a nucleotide sequence identical to or complementary to at least about 15-30, particularly at least 17, sequential nucleotides within the polyribonucleotide sequence coding for a specific polypeptide or protein.
- Exemplary such expression inhibitory molecules include ribozymes, microRNAs, double stranded siRNA molecules, self-complementary single-stranded siRNA molecules, genetic antisense constructs, and synthetic RNA antisense molecules with modified stabilized backbones.
- RNAi inhibitor refers to any molecule that can down regulate, reduce or inhibit RNA interference function or activity in a cell or organism.
- An RNAi inhibitor can down regulate, reduce or inhibit RNAi (e.g., RNAi mediated cleavage of a target polynucleotide, translational inhibition, or transcriptional silencing) by interaction with or interfering with the function of any component of the RNAi pathway, including protein components such as RISC, or nucleic acid components such as miRNAs or siRNAs.
- a RNAi inhibitor can be an siNA molecule, an antisense molecule, an aptamer, or a small molecule that interacts with or interferes with the function of RISC, a miRNA, or an siRNA or any other component of the RNAi pathway in a cell or organism.
- RNAi e.g., RNAi mediated cleavage of a target polynucleotide, translational inhibition, or transcriptional silencing
- a RNAi inhibitor of the invention can be used to modulate (e.g., down regulate) the expression of a target gene.
- microRNA or "miRNA” or “miR” as used herein refers to its meaning as is generally accepted in the art. More specifically, the term refers a small double-stranded RNA molecules that regulate the expression of target messenger RNAs either by mRNA cleavage, translational repression/inhibition or heterochromatic silencing (see for example Ambros, 2004, Nature, 431 , 350-355; Barrel, 2004, Cell, 1 16, 281-297; Cullen, 2004, Virus Research., 102, 3-9; He et al, 2004, Nat. Rev.
- RNA, 12: 192-197 As used herein, the term includes mature single stranded miRNAs, precursor miRNAs (pre-miR), and variants thereof, which may be naturally occurring. In some instances, the term "miRNA” also includes primary miRNA transcripts and duplex miRNAs.
- fragment of a polynucleotide' relates to oligonucleotides that comprise a stretch of contiguous nucleic acid residues that exhibit substantially a similar, but not necessarily identical, activity as the complete sequence.
- 'fragment' may refer to a oligonucleotide comprising a nucleic acid sequence of at least 5 nucleic acid residues (preferably, at least 10 nucleic acid residues, at least 15 nucleic acid residues, at least 20 nucleic acid residues, at least 25 nucleic acid residues, at least 40 nucleic acid residues, at least 50 nucleic acid residues, at least 60 nucleic residues, at least 70 nucleic acid residues, at least 80 nucleic acid residues, at least 90 nucleic acid residues, at least 100 nucleic acid residues, at least 125 nucleic acid residues, at least 150 nucleic acid residues, at least 175 nucleic acid residues, at least 200 nucleic acid residues, or at least 250 nucleic acid residues) of the nucleic acid sequence of said complete sequence.
- nucleic acid residues preferably, at least 10 nucleic acid residues, at least 15 nucleic acid residues, at least 20 nucleic acid residues
- the term 'fragment of a polypeptide' relates to peptides, oligopeptides, polypeptides, proteins, monomers, subunits and enzymes that comprise a stretch of contiguous amino acid residues, and exhibit substantially a similar, but not necessarily identical, functional or expression activity as the complete sequence.
- ' fragment' may refer to a peptide or polypeptide comprising an amino acid sequence of at least 5 amino acid residues (preferably, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, at least 150 amino acid residues, at least 175 amino acid residues, at least 200 amino acid residues, or at least 250 amino acid residues) of the amino acid sequence of said complete sequence.
- amino acid residues preferably, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at
- the term 'hybridization' means any process by which a strand of nucleic acid binds with a complementary strand through base pairing.
- the term 'hybridization complex' refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases.
- a hybridization complex may be formed in solution (for example, COt or ROt analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (for example, paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).
- stringent conditions refers to conditions that permit hybridization between polynucleotides and the claimed polynucleotides.
- Stringent conditions can be defined by salt concentration, the concentration of organic solvent, for example, formamide, temperature, and other conditions well known in the art. In particular, reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature can increase stringency.
- standard hybridization conditions' refers to salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and wash. However, one skilled in the art will appreciate that such 'standard hybridization conditions' are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like.
- Standard hybridization conditions are whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20NC below the predicted or determined Tm with washes of higher stringency, if desired.
- the term 'inhibit' or 'inhibiting', in relationship to the term 'response' means that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.
- the term 'inhibition' refers to the reduction, down regulation of a process or the elimination of a stimulus for a process, which results in the absence or minimization of the expression or activity of a protein or polypeptide.
- the term 'induction' refers to the inducing, up-regulation, or stimulation of a process, which results in the expression, enhanced expression, activity, or increased activity of a protein or polypeptide.
- ligand' means an endogenous, naturally occurring molecule specific for an endogenous, naturally occurring receptor.
- salts refers to the non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds which inhibit the expression or activity of TARGETS as disclosed herein. These salts can be prepared in situ during the final isolation and purification of compounds useful in the present invention.
- polypeptide' relates to proteins (such as TARGETS), proteinaceous molecules, fragments of proteins, monomers or portions of polymeric proteins, peptides, oligopeptides and enzymes (such as kinases, proteases, GPCR's etc.).
- polynucleotide means a polynucleic acid, in single or double stranded form, and in the sense or antisense orientation, complementary polynucleic acids that hybridize to a particular polynucleic acid under stringent conditions, and polynucleotides that are homologous in at least about 60 percent of its base pairs, and more particularly 70 percent of its base pairs are in common, particularly 80 percent, most particularly 90 per cent, and in a special embodiment 100 percent of its base pairs.
- the polynucleotides include polyribonucleic acids, polydeoxyribonucleic acids, and synthetic analogues thereof.
- nucleic acids with modified backbones such as peptide nucleic acid (PNA), polysiloxane, and 2'-0-(2-methoxy)ethylphosphorothioate.
- PNA peptide nucleic acid
- polysiloxane polysiloxane
- 2'-0-(2-methoxy)ethylphosphorothioate The polynucleotides are described by sequences that vary in length, that range from about 10 to about 5000 bases, particularly about 100 to about 4000 bases, more particularly about 250 to about 2500 bases.
- One polynucleotide embodiment comprises from about 10 to about 30 bases in length.
- polynucleotide is the polyribonucleotide of from about 17 to about 22 nucleotides, more commonly described as small interfering RNAs (siRNAs - double stranded siRNA molecules or self-complementary single-stranded siRNA molecules (shRNA)).
- small interfering RNAs siRNAs - double stranded siRNA molecules or self-complementary single-stranded siRNA molecules (shRNA)
- nucleic acids with modified backbones such as peptide nucleic acid (PNA), polysiloxane, and 2'-0-(2- methoxy)ethylphosphorothioate, or including non-naturally occurring nucleic acid residues, or one or more nucleic acid substituents, such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl-, chloro-, and methanocarbanucleosides, or a reporter molecule to facilitate its detection.
- Polynucleotides herein are selected to be 'substantially' complementary to different strands of a particular target DNA sequence.
- the polynucleotides must be sufficiently complementary to hybridize with their respective strands. Therefore, the polynucleotide sequence need not reflect the exact sequence of the target sequence.
- a non-complementary nucleotide fragment may be attached to the 5' end of the polynucleotide, with the remainder of the polynucleotide sequence being complementary to the strand.
- non-complementary bases or longer sequences can be interspersed into the polynucleotide, provided that the polynucleotide sequence has sufficient complementarity with the sequence of the strand to hybridize therewith under stringent conditions or to form the template for the synthesis of an extension product.
- the term 'preventing' or 'prevention' refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop) in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.
- the term 'prophylaxis' is related to and encompassed in the term 'prevention', and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease.
- prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
- the term 'subject' includes humans and other mammals.
- the term 'TARGET' or 'TARGETS' means the protein(s) identified in accordance with the assays described herein and determined to be involved in fibroblast migration and differentiation.
- the term TARGET or TARGETS includes and contemplates alternative species forms, isoforms, and variants, such as splice variants, allelic variants, alternate in frame exons, and alternative or premature termination or start sites, including known or recognized isoforms or variants thereof such as indicated in Table 1.
- the NCBI accession numbers are provided to assist a skilled person to identify the transcripts and polypeptides.
- the term TARGET or TARGETS is not limited to those particular versions of the sequences and encompasses functional variants of nucleic acids and polypeptides corresponding to those sequences.
- 'Therapeutically effective amount' or 'effective amount' means that amount of a compound or agent that will elicit the biological or medical response of a subject that is being sought by or is accepted by a medical doctor or other clinician.
- the term 'treating' or 'treatment' of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). Accordingly, 'treating' refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treating include those already with the disorder as well as those in which the disorder is to be prevented.
- the related term 'treatment,' as used herein, refers to the act of treating a disorder, symptom, disease or condition. In another embodiment 'treating' or 'treatment' refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
- 'treating' or 'treatment' refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter or of a physiologically measurable parameter), or both.
- 'treating' or 'treatment' relates to slowing the progression of the disease.
- vectors also relates to plasmids as well as to viral vectors, such as recombinant viruses, or the nucleic acid encoding the recombinant virus.
- vertebrate cells means cells derived from animals having vertebral structure, including fish, avian, reptilian, amphibian, marsupial, and mammalian species. Preferred cells are derived from mammalian species, and most preferred cells are human cells. Mammalian cells include feline, canine, bovine, equine, caprine, ovine, porcine, murine, such as mice and rats, and rabbits.
- fibrotic diseases refers to diseases characterized by excessive or persistent scarring, particularly due to excessive or abnormal production, deposition of extracellular matrix, and are that are associated with the abnormal accumulation of cells and/or fibronectin and/or collagen and/or increased fibroblast recruitment and include but are not limited to fibrosis of individual organs or tissues such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and digestive tract.
- fibrotic diseases refers to idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), c o l lagen vascul ar dis e as e , alveo lar proteino sis , l angerhans c e ll granulo mato sis , lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, bleomycin induced pulmonary fibrosis, chronic asthma, silicosis, asbestos induced pulmonary fibrosis
- IPPF
- fibroblast refers to cells derived from mesenchymal progenitor cells and which are present in flattened, irregular-shaped connective tissue and provide the structural framework of cell(s), ubiquitous in fibrous connective tissue by generating and/or secreting components of the extracellular matrix factors, including type I collagen and hyaluronic acid.
- myofibroblast refers to fibroblasts that transitioned from fibroblast into fibroblasts that are differentiated towards a smooth muscle cell-like phenotype, and which express high levels of alpha smooth muscle actin (aSMA) and are positive for aSMA.
- aSMA alpha smooth muscle actin
- fibroblast migration and differentiation refers to processes of fibroblast migration and differentiation (or alternatively, transition) into myofibroblasts respectively. Such processes are known to play role in onset and development of fibrotic conditions. In particular aspect, fibroblast differentiation and migration do not have to occur simultaneously. Each of these processes independently contributes to the development of fibrotic conditions. Fibroblast migration may lead to excessive accumulation of fibroblasts which directly or indirectly contribute to fibrosis. Fibroblast to myofibroblast differentiation (or transition) leads to the formation of cell types that produce excessive extracellular matrix factors contributing to onset and development of fibrosis
- Applicant's invention is relevant to the treatment, prevention and alleviation of a fibrotic disease.
- the present invention is based on extensive work by the present inventors to develop an in vitro (cell-free or cell based) assay system suitable to provide a scientifically valid substitute for the naturally occurring in vivo process of fibroblast migration and differentiation.
- the process of fibroblast migration and differentiation is known to be involved in fibrosis, however it is a complex process.
- the present invention provides an artificial model for the natural system which is suitable for the identification of compounds able to inhibit fibroblast migration and differentiation, and, thus, identify compounds that may be useful in the treatment and/or prevention of fibrosis.
- the present invention provides methods for assaying for drug candidate compounds useful in treatment of fibrotic conditions, comprising contacting the compound with a cell expressing a TARGET, and determining the relative amount or degree of inhibition of fibroblast migration and differentiation in the presence and/or absence of the compound.
- the present invention provides methods for assaying for drug candidate compounds useful in treatment of fibrotic conditions, particularly useful in reducing fibroblast migration and / or differentiation, comprising contacting the compound with a cell expressing a TARGET, and determining the relative amount or degree of inhibition of the expression or activity of the TARGET, whereby inhibition of expression or activity of the TARGET is associated with or results in inhibition of or reduced fibroblast migration and / or differentiation in the presence and/or absence of the compound.
- Such methods may be used to identify target proteins that act to inhibit said differentiation; alternatively, they may be used to identify compounds that down-regulate or inhibit the expression or activity of TARGET proteins.
- the invention provides methods for assaying for drug candidate compounds useful in the treatment of fibrosis, comprising contacting the compound with a TARGET, under conditions wherein the expression or activity of the TARGET may be measured, and determining whether the TARGET expression or activity is altered in the presence of the compound, contacting a population of fibroblasts with said test compound and measuring a property related to fibroblast migration or differentiation. Exemplary such methods can be designed and determined by the skilled artisan. Particular such exemplary methods are provided herein.
- the present invention is based on the inventors' discovery that the TARGET polypeptides and their encoding nucleic acids, identified as a result of screens described below in the Examples, are factors involved in the fibrosis and in particular in fibroblast migration and differentiation.
- a reduced activity or expression of the TARGET polypeptides and/or their encoding polynucleotides is causative, correlative or associated with reduced or inhibited fibroblast migration and differentiation.
- a reduced activity or expression of the TARGET polypeptides and/or their encoding polynucleotides is causative, correlative or associated with decrease of the markers of fibroblast differentiation.
- the TARGET polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 57-112 as listed in Table 1.
- IP IP
- a particular embodiment of the invention comprises the GPCR TARGETS identified as SEQ ID NO: 57, 58 and 84.
- a particular embodiment of the invention comprises the kinase TARGETS identified as SEQ ID NO: 60, 61, 62, 63 and 83.
- a particular embodiment of the invention comprises the protease TARGET identified as SEQ ID NO: 59 and 65.
- a particular embodiment of the invention comprises the secreted/extracellular TARGETS identified as SEQ ID NO: 64 and 76.
- a particular embodiment of the invention comprises the transferase TARGETS identified as SEQ ID NO: 66, 77- 82.
- a particular embodiment of the invention comprises the oxidoreductase TARGET identified as SEQ ID NO: 67-70.
- a particular embodiment of the invention comprises the ion channel TARGETS identified as SEQ ID NO: 71-75, 85-112.
- the present invention relates to a method for identifying a compound useful for the treatment of fibrosis, said method comprising:
- the present invention relates to a method for identifying a compound that inhibits fibroblast migration and differentiation, said method comprising:
- the present invention relates to a method for identifying a compound that inhibits fibroblast migration or differentiation, said method comprising:
- a test compound a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 57-112, fragments and functional derivatives thereof or with a nucleic acid encoding an amino acid selected from the group consisting of SEQ ID NOs: 57-112 or a functional derivative thereof;
- nucleic acid encoding an amino acid selected from the group consisting of SEQ ID NOs: 57-112 or a functional derivative thereof may be selected from the group consisting of SEQ ID NOs: 1-56.
- the order of taking these measurements is not believed to be critical to the practice of the present invention, which may be practiced in any order.
- the method steps (c) and (d) may be performed before performing steps (a) and (b). For example, one may first perform a screening assay of a set of compounds for which no information is known respecting the compounds' binding affinity for the polypeptide. Alternatively, one may screen a set of compounds identified as having binding affinity for a polypeptide domain, or a class of compounds identified as being an inhibitor of the polypeptide.
- steps (a)-(d) method may also be performed simultaneously in a cell-based assay by contacting a test compound with a population of fibroblasts, measuring a binding affinity of the test compound to a TARGET polypeptide and a property related to fibroblast migration or differentiation, and identifying a compound capable of inhibiting fibroblast migration or differentiation and which demonstrates binding affinity to said polypeptide.
- the binding affinity of a compound with the polypeptide TARGET can be measured by methods known in the art, such as using surface plasmon resonance biosensors (Biacore ® ), by saturation binding analysis with a labeled compound (for example, Scatchard and Lindmo analysis), by differential UV spectrophotometer, fluorescence polarization assay, Fluor ometric Imaging Plate Reader (FLIPR ® ) system, Fluorescence resonance energy transfer, and Bioluminescence resonance energy transfer.
- the binding affinity of compounds can also be expressed in dissociation constant (Kd) or as IC 5 o or EC 5 o.
- Kd dissociation constant
- IC 5 o represents the concentration of a compound that is required for 50% inhibition of binding of another ligand to the polypeptide.
- the EC 5 o represents the concentration required for obtaining 50% of the maximum effect in any assay that measures TARGET function.
- the dissociation constant, Kd is a measure of how well a ligand binds to the polypeptide, it is equivalent to the ligand concentration required to saturate exactly half of the binding-sites on the polypeptide.
- Compounds with a high affinity binding have low Kd, IC 5 o and EC 5 o values, for example, in the range of 100 nM to 1 pM; a moderate- to low-affinity binding relates to high Kd, IC 5 o and EC 5 o values, for example in the micromolar range.
- the assay method includes contacting a TARGET polypeptide with a compound that exhibits a binding affinity in the micromolar range.
- the binding affinity exhibited is at least 10 micromolar.
- the binding affinity is at least 1 micromolar.
- the binding affinity is at least 500 nanomolar.
- test compound is selected based its ability to bind to a TARGET class or from a known libraries of compounds having ability to bind to a TARGET class.
- the present invention relates to a method for identifying a compound useful for the treatment of fibrosis, said method comprising:
- the present invention relates to a method for identifying a compound that inhibits fibroblast migration and differentiation, said method comprising:
- the present invention relates to a method for identifying a compound that inhibits fibroblast migration and differentiation, said method comprising:
- nucleic acid encoding an amino acid selected from the group consisting of SEQ ID NOs: 57-112 or a functional derivative thereof may be selected from the group consisting of SEQ ID NOs: 1-56.
- steps (c) and (d) may be performed before performing steps (a) and (b). For example, one may first perform a screening assay of a set of compounds for which no information is known respecting the compounds' binding affinity for the polypeptide. Alternatively, one may screen a set of compounds identified as having binding affinity for a polypeptide domain, or a class of compounds identified as being an inhibitor of the polypeptide.
- Table 1 lists the TARGETS identified using applicants' knock-down library in the fibroblast migration and differentiation assays exemplified herein, including the class of polypeptides identified.
- TARGETS have been identified in polypeptide classes including kinases, proteases, enzymes, ion channels, GPCRs, and extracellular proteins, for instance.
- a skilled artisan would be aware of different methods of measuring activity of those classes both in cell-free preparations as well in cell- based assays. A variety of methods exists and might be adapted to a particular target. Those adaptations are a matter of routine experimentation and rely on the existent techniques and methods. Some exemplary methods are described herein.
- Ion channels are membrane protein complexes and their function is to facilitate the diffusion of ions across biological membranes.
- Membranes, or phospholipid bilayers build a hydrophobic, low dielectric barrier to hydrophilic and charged molecules.
- Ion channels provide a high conducting, hydrophilic pathway across the hydrophobic interior of the membrane.
- the activity of an ion channel can be measured using classical patch clamping.
- High-throughput fluorescence-based or tracer-based assays are also widely available to measure ion channel activity. These fluorescent-based assays screen compounds on the basis of their ability to either open or close an ion channel thereby changing the concentration of specific fluorescent dyes across a membrane.
- the tracer-based assay the changes in concentration of the tracer within and outside the cell are measured by radioactivity measurement or gas absorption spectrometry.
- substrates are used in which a fluorescent group is linked to a quencher through a peptide sequence that is a substrate that can be cleaved by the target protease. Cleavage of the linker separates the fluorescent group and quencher, giving rise to an increase in fluorescence.
- G-protein coupled receptors are capable of activating an effector protein, resulting in changes in second messenger levels in the cell.
- the TARGETS represented by SEQ ID NO: 57, 58 and 84 are GPCRs.
- the activity of a GPCR can be measured by measuring the activity level of such second messengers.
- Two important and useful second messengers in the cell are cyclic AMP (cAMP) and Ca 2+ .
- cAMP cyclic AMP
- Ca 2+ The activity levels can be measured by methods known to persons skilled in the art, either directly by ELISA or radioactive technologies or by using substrates that generate a fluorescent or luminescent signal when contacted with Ca 2+ or indirectly by reporter gene analysis.
- the activity level of the one or more secondary messengers may typically be determined with a reporter gene controlled by a promoter, wherein the promoter is responsive to the second messenger.
- Promoters known and used in the art for such purposes are the cyclic-AMP responsive promoter that is responsive for the cyclic-AMP levels in the cell, and the NF-AT responsive promoter that is sensitive to cytoplasmic Ca 2+ -levels in the cell.
- the reporter gene typically has a gene product that is easily detectable.
- the reporter gene can either be stably infected or transiently transfected in the host cell.
- Useful reporter genes are alkaline phosphatase, enhanced green fluorescent protein, destabilized green fluorescent protein, luciferase and ⁇ -galactosidase.
- the present relation relates to a method for identifying a compound useful for the treatment of fibrosis, said method comprising
- the present relation relates to a method for identifying a compound that inhibits fibroblast migration and differentiation, said method comprising
- the method steps of the invention related to measuring of binding to a TARGET or activity are performed with a population of mammalian cells, in particular human cells, which have been engineered so as to express said TARGET polypeptide.
- the methods of the invention are performed using a population of fibroblasts, which have been engineered so as to express said TARGET polypeptide. This can be achieved by expression of the TARGET polypeptide in the cells using appropriate techniques known to a skilled person. In a specific embodiment, this can be achieved by over-expression of the TARGET polypeptide in the cells using appropriate techniques known to a skilled person.
- the method of the invention maybe performed with a population of fibroblasts which are known to naturally express said TARGET polypeptide.
- the measurements of expression and/or amount of a TARGET polypeptide and a measurement of a property related to fibroblast migration or differentiation can be done in separate steps using different populations of macrophage cells.
- the order of taking these measurements is not believed to be critical to the practice of the present invention, which may be practiced in any order.
- the measurements in steps (b) and (c) can also be performed in reverse order.
- it is sufficient to measure at least one property related to fibroblast migration or differentiation a skilled person may perform a series of measurements and measure several of said properties.
- One particular means of measuring the activity or expression of the polypeptide is to determine the amount of said polypeptide using a polypeptide binding agent, such as an antibody, or to determine the activity of said polypeptide in a biological or biochemical measure, for instance the amount of phosphorylation of a target of a kinase polypeptide.
- TARGET gene expression can be measured using techniques well-known to a skilled artisan. Particular examples of such techniques include northern analysis or real-time PCR. Those methods are indicative of the presence of nucleic acids encoding TARGETS in a sample, and thereby correlates with expression of the transcript from the polynucleotide.
- the population of cells may be exposed to the compound or the mixture of compounds through different means, for instance by direct incubation in the medium, or by nucleic acid transfer into the cells.
- transfer may be achieved by a wide variety of means, for instance by direct transfection of naked isolated DNA, or RNA, or by means of delivery systems, such as recombinant vectors.
- Other delivery means such as liposomes, or other lipid-based vectors may also be used.
- the nucleic acid compound is delivered by means of a (recombinant) vector such as a recombinant virus.
- animal models of fibrotic diseases may be utilized by the skilled artisan to further or additionally screen, assess, and / or verify the agents or compounds identified in the present invention, including further assessing TARGET modulation in vivo.
- animal models include, but are not limited to bleomycin, irradiation, silica, (inducible) transgenic mouse, FITC and adoptive transfer models for lung fibrosis (Bethany et al, 2008), collagen 4 a3 (COL4A3)-deficiency, nephrotoxic serum nephritis and unilateral ureteral obstruction models for renal fibrosis (Zeisberget al, 2005) and CCL4 intoxication model for liver fibrosis (Starkel et al, 2011)
- a population of fibroblasts in the methods of the invention does not have to be pure or require a particular degree of purity.
- a population of mammalian cells wherein some of said cells are fibroblasts cells is sufficient to practice the methods of present invention. It should be understood that a population of fibroblasts can be also obtained directly from an organ or alternatively grown using appropriate medium. Fibroblasts can be obtained from commercial vendors like Epithelix or LONZA.
- the methods may additionally comprise the step of comparing the compound to be tested to a control. Suitable controls should always be in place to insure against false positive readings.
- the screening method comprises the additional step of comparing the compound to a suitable control.
- the control may be a cell or a sample that has not been in contact with the test compound.
- the control may be a cell that does not express the TARGET; for example in one aspect of such an embodiment the test cell may naturally express the TARGET and the control cell may have been contacted with an agent, e.g. a siRNA, which inhibits or prevents expression of the TARGET.
- the cell in its native state does not express the TARGET and the test cell has been engineered so as to express the TARGET, so that in this embodiment, the control could be the untransformed native cell.
- the control may also alternatively utilize either a known inhibitor of fibroblasts migration or differentiation, or a compound known not to have any significant effect on fibroblasts migration or differentiation. Whilst exemplary controls are described herein, this should not be taken as limiting; it is within the scope of a person of skill in the art to select appropriate controls for the experimental conditions being used.
- Examples of negative controls include, but not limited to, cells that have been not treated with any compound, cells treated with a compound known not to be an inhibitor of fibroblast migration or differentiation, compounds known not to interfere with the pathways involved in fibroblast migration or differentiation.
- Examples of positive controls include, but not limited to, cells contacted with compounds known to inhibit activity or expression of CXCR4, COLIAl, PIK3C3, PGK and MAPK14, cells contacted with a compound known to inhibit fibroblast migration or differentiation.
- binding and activity testing methods are performed in an in vitro cell-free preparation.
- binding and activity testing in the invention methods is performed in a cell.
- the invention methods activity and binding testing is performed in a mammalian cell. More specifically these steps are performed in fibroblasts. In particular embodiment these steps are performed in human lung fibroblasts. In a specific aspect of the invention the methods are performed with a population of mammalian cells present in a monolayer, preferably said mammalian cells are fibroblasts and more preferably said mammalian cells are human lung fibroblasts.
- the cells expressing the polypeptides may be cells naturally expressing the polypeptides, or the cells may be may be transfected to express the polypeptides. Also, the cells may be transduced to overexpress the polypeptide, or may be transfected to express a non- endogenous form of the polypeptide, which can be differentially assayed or assessed.
- the polynucleotide expressing the TARGET polypeptide in cells might be included within a vector.
- the polynucleic acid is operably linked to signals enabling expression of the nucleic acid sequence and is introduced into a cell utilizing, particularly, recombinant vector constructs, which will express the nucleic acid once the vector is introduced into the cell.
- a variety of viral-based systems are available, including adenoviral, retroviral, adeno-associated viral, lentiviral, herpes simplex viral or a sendai viral vector systems. All may be used to introduce and express expressing a TARGET polypeptide in the target cells.
- the methods of the invention involve measurement of a property is related to fibroblast migration.
- a property is related to fibroblast migration.
- fibroblast migration There are different ways to measure fibroblast migration.
- such property is a measure of scratch in a monolayer of fibroblasts.
- transwell system / Boyden Chamber assays and time-lapse experiments can be used to measure fibroblast migration.
- the methods of the invention utilize cells that have been triggered by a factor which induces fibroblast migration (migration-inducing factor). Many of such factors have been described in literature and they are well-known to a skilled person.
- the methods of the invention utilize cells that have been triggered by one or more migration-inducing factors selected from the group consisting of is selected from the group consisting of CCLs (CCL3, CCL7, CCL13, CCL27, CCL22, CCL21, CCL15, CCL17, CCL18, CCL19, CCL20), CXCLs (CXCLl, CXCL8, CXCLl 2), IL13, CTGF, PDGF-BB.
- the methods of the invention utilize cells that have been triggered by PDGF-BB.
- the cells are triggered by a migration- inducing factor and serum.
- the assay methods of the invention involve measurement of a property related to the differentiation of fibroblasts into myofibroblasts.
- the assay methods of the invention involve measurement of a decrease in production and/or expression of a marker of fibroblast-to-myofibroblast differentiation.
- fibroblast differentiation markers are known to a skilled person. The selection of such markers depends on the availability of reagents, scale of the practiced assay methods and other factors related to a specific assay design.
- fibroblast differentiation marker is selected from the group consisting of a-smooth muscle actin, collagens, and connective tissue growth factor.
- the said marker is ⁇ -smooth muscle actin.
- the methods of the invention utilize cells that have been triggered by a fibroblast-to-myofibroblast differentiation factor.
- said fibroblast-to- myofibroblast differentiation factor is TGF .
- MSD Meso Scale Discovery platform
- MSD technology uses micro-plates with carbon electrodes integrated at the bottom of the plates; Biological reagents, immobilized to the carbon simply by passive adsorption, retain high biological activity.
- MSD assays use electro-chemiluminescent labels for ultra-sensitive detection.
- the detection process is initiated at electrodes located at the bottom of the micro-plates. Labels near the electrode only are excited and detected reducing background signal.
- the antibodies for such assay might be purchased from different producers and the skilled artisan is in the position to choose correct antibodies to perform the assay.
- the expression levels of fibroblast differentiation markers can be measured using known methods including quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR).
- qPCR is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule.
- Real Time- PCR enables both detection and quantification.
- the quantity can be either an absolute number of copies or a relative amount when normalized to DNA input or additional normalizing genes.
- test compound is selected from the group consisting of an antisense polynucleotide, a ribozyme, short-hairpin RNA (shRNA), microRNA (miRNA) and a small interfering RNA (siRNA).
- a special embodiment of these methods comprises an expression-inhibitory agent selected from the group consisting of antisense RNA, antisense oligodeoxynucleotide (ODN), a ribozyme that cleaves the polyribonucleotide coding for SEQ ID NO: 57-112, a small interfering RNA (siRNA) or microRNA (miRNA) that is sufficiently homologous to a portion of the polyribonucleotide corresponding to SEQ ID NO: 1-56, such that the siRNA interferes with the translation of the TARGET polyribonucleotide to the TARGET polypeptide.
- ODN antisense oligodeoxynucleotide
- a ribozyme that cleaves the polyribonucleotide coding for SEQ ID NO: 57-112
- siRNA small interfering RNA
- miRNA microRNA
- Antisense nucleic acids of the invention are particularly nucleic acid fragments capable of specifically hybridizing with all or part of a nucleic acid encoding a TARGET polypeptide or the corresponding messenger RNA.
- antisense nucleic acids may be designed which decrease expression of the nucleic acid sequence capable of encoding a TARGET polypeptide by inhibiting splicing of its primary transcript. Any length of antisense sequence is suitable for practice of the invention so long as it is capable of down-regulating or blocking expression of a nucleic acid coding for a TARGET.
- the antisense sequence is at least about 15-30, and particularly at least 17 nucleotides in length.
- the preparation and use of antisense nucleic acids, DNA encoding antisense RNAs and the use of oligo and genetic antisense is known in the art.
- a test compound comprises a nucleic acid sequence complementary to, or engineered from, a naturally- occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a TARGET polynucleotide.
- Antisense oligonucleotides may be selected on the basis of secondary structure (Wickstrom et al (1991) in Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, Wickstrom, ed., Wiley-Liss, Inc., New York, pp. 7-24; Lima et al. (1992) Biochem. 31 :12055-12061). Schmidt and Thompson (U.S.
- Patent 6,416,951 describe a method for identifying a functional antisense agent comprising hybridizing an RNA with an oligonucleotide and measuring in real time the kinetics of hybridization by hybridizing in the presence of an intercalation dye or incorporating a label and measuring the spectroscopic properties of the dye or the label's signal in the presence of unlabelled oligonucleotide.
- any of a variety of computer programs may be utilized which predict suitable antisense oligonucleotide sequences or antisense targets utilizing various criteria recognized by the skilled artisan, including for example the absence of self-complementarity, the absence of hairpin loops, the absence of stable homodimer and duplex formation (stability being assessed by predicted energy in kcal/mol).
- Examples of such computer programs are readily available and known to the skilled artisan and include the OLIGO 4 or OLIGO 6 program (Molecular Biology Insights, Inc., Cascade, CO) and the Oligo Tech program (Oligo Therapeutics Inc., Wilsonville, OR).
- antisense oligonucleotides suitable in the present invention may be identified by screening an oligonucleotide library, or a library of nucleic acid molecules, under hybridization conditions and selecting for those which hybridize to the target RNA or nucleic acid (see for example U.S. Patent 6,500,615). Mishra and Toulme have also developed a selection procedure based on selective amplification of oligonucleotides that bind target (Mishra et al (1994) Life Sciences 317:977-982).
- Oligonucleotides may also be selected by their ability to mediate cleavage of target RNA by RNAse H, by selection and characterization of the cleavage fragments (Ho et al (1996) Nucl Acids Res 24:1901-1907; Ho et al (1998) Nature Biotechnology 16:59-630). Generation and targeting of oligonucleotides to GGGA motifs of RNA molecules has also been described (U.S. Patent 6,277,981).
- the antisense nucleic acids are particularly oligonucleotides and may consist entirely of deoxyribo-nucleotides, modified deoxyribonucleotides, or some combination of both.
- the antisense nucleic acids can be synthetic oligonucleotides.
- the oligonucleotides may be chemically modified, if desired, to improve stability and/or selectivity.
- Specific examples of some particular oligonucleotides envisioned for this invention include those containing modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages.
- oligonucleotides are susceptible to degradation by intracellular nucleases, the modifications can include, for example, the use of a sulfur group to replace the free oxygen of the phosphodiester bond. This modification is called a phosphorothioate linkage.
- Phosphorothioate antisense oligonucleotides are water soluble, polyanionic, and resistant to endogenous nucleases.
- the RNA-DNA duplex activates the endogenous enzyme ribonuclease (RNase) H, which cleaves the mRNA component of the hybrid molecule.
- RNase ribonuclease
- Oligonucleotides may also contain one or more substituted sugar moieties.
- Particular oligonucleotides comprise one of the following at the 2' position: OH, SH, SCH3, F, OCN, heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide.
- antisense oligonucleotides with phosphoramidite and polyamide (peptide) linkages can be synthesized. These molecules should be very resistant to nuclease degradation.
- chemical groups can be added to the 2' carbon of the sugar moiety and the 5 carbon (C- 5) of pyrimidines to enhance stability and facilitate the binding of the antisense oligonucleotide to its TARGET site. Modifications may include 2'-deoxy, O-pentoxy, O-propoxy, O-methoxy, fluoro, methoxyethoxy phosphorothioates, modified bases, as well as other modifications known to those of skill in the art.
- Ribozymes are catalytic RNA molecules (RNA enzymes) that have separate catalytic and substrate binding domains.
- the substrate binding sequence combines by nucleotide complementarity and, possibly, non-hydrogen bond interactions with its TARGET sequence.
- the catalytic portion cleaves the TARGET RNA at a specific site.
- the substrate domain of a ribozyme can be engineered to direct it to a specified mRNA sequence. The ribozyme recognizes and then binds a TARGET mRNA through complementary base pairing.
- the ribozyme acts enzymatically to cut the TARGET mRNA. Cleavage of the mRNA by a ribozyme destroys its ability to direct synthesis of the corresponding polypeptide. Once the ribozyme has cleaved its TARGET sequence, it is released and can repeatedly bind and cleave at other mRNAs.
- Exemplary ribozyme forms include a hammerhead motif, a hairpin motif, a hepatitis delta virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) motif or Neurospora VS RNA motif.
- Ribozymes possessing a hammerhead or hairpin structure are readily prepared since these catalytic RNA molecules can be expressed within cells from eukaryotic promoters (Chen, et al. (1992) Nucleic Acids Res. 20:4581-9).
- a ribozyme of the present invention can be expressed in eukaryotic cells from the appropriate DNA vector. If desired, the activity of the ribozyme may be augmented by its release from the primary transcript by a second ribozyme (Ventura, et al. (1993) Nucleic Acids Res. 21 :3249-55).
- Ribozymes may be chemically synthesized by combining an oligodeoxyribonucleotide with a ribozyme catalytic domain (20 nucleotides) flanked by sequences that hybridize to the TARGET mRNA after transcription.
- the oligodeoxyribonucleotide is amplified by using the substrate binding sequences as primers.
- the amplification product is cloned into a eukaryotic expression vector.
- Ribozymes are expressed from transcription units inserted into DNA, RNA, or viral vectors. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on nearby gene regulatory sequences. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Gao and Huang, (1993) Nucleic Acids Res. 21 :2867-72). It has been demonstrated that ribozymes expressed from these promoters can function in mammalian cells (Kashani-Sabet, et al. (1992) Antisense Res. Dev. 2:3-15).
- antisense polynucleotide siRNA or shRNA comprising an antisense strand of 17-25 nucleotides complementary to a sense strand, wherein said sense strand is selected from 17-25 continuous nucleotides of a TARGET polynucleotide.
- a particular inhibitory agent is a small interfering RNA (siRNA, particularly small hairpin RNA, "shRNA”).
- siRNA particularly shRNA, mediate the post-transcriptional process of gene silencing by double stranded RNA (dsRNA) that is homologous in sequence to the silenced RNA.
- dsRNA double stranded RNA
- siRNA according to the present invention comprises a sense strand of 15-30, particularly 17-30, most particularly 17-25 nucleotides complementary or homologous to a contiguous 17-25 nucleotide sequence selected from the group of sequences described in SEQ ID NO: 1-56, particularly from the group of sequences described in SEQ ID NOs: 129-171, and an antisense strand of 15-30, particularly 17-30, most particularly 17-25, more specifically 19-21 nucleotides complementary to the sense strand.
- More particular siRNA according to the present invention comprises a sense strand selected from the group of sequences comprising SEQ ID NOs: 129-171.
- the most particular siRNA comprises sense and anti-sense strands that are 100 per cent complementary to each other and the TARGET polynucleotide sequence.
- the siRNA further comprises a loop region linking the sense and the antisense strand.
- a self-complementing single stranded shRNA molecule polynucleotide according to the present invention comprises a sense portion and an antisense portion connected by a loop region linker.
- the loop region sequence is 4-30 nucleotides long, more particularly 5-15 nucleotides long and most particularly 8 or 12 nucleotides long.
- the linker sequence is UUGCUAUA or GUUUGCUAUAAC (SEQ ID NO: 172).
- Self-complementary single stranded siRNAs form hairpin loops and are more stable than ordinary dsRNA. In addition, they are more easily produced from vectors.
- the siRNA can be modified to confirm resistance to nucleolytic degradation, or to enhance activity, or to enhance cellular distribution, or to enhance cellular uptake, such modifications may consist of modified internucleoside linkages, modified nucleic acid bases, modified sugars and/or chemical linkage the siRNA to one or more moieties or conjugates.
- the nucleotide sequences are selected according to siRNA designing rules that give an improved reduction of the TARGET sequences compared to nucleotide sequences that do not comply with these siRNA designing rules (For a discussion of these rules and examples of the preparation of siRNA, WO 2004/094636 and US 2003/0198627, are hereby incorporated by reference).
- MicroRNAs are small non-coding RNAs, belonging to a class of regulatory molecules found in many eukaryotic species that control gene expression by binding to complementary sites on target messenger RNA (mRNA) transcripts.
- In vivo miRNAs are generated from larger RNA precursors (termed pri-miRNAs) that are processed in the nucleus into approximately 70 nucleotide pre-miRNAs, which fold into imperfect stem-loop structures.
- the pre-miRNAs undergo an additional processing step within the cytoplasm where mature miRNAs of 18-25 nucleotides in length are excised from one side of the pre-miRNA hairpin by an RNase III enzyme.
- miRNAs have been shown to regulate gene expression in two ways. First, miRNAs binding to protein-coding mRNA sequences that are exactly complementary to the miRNA induce the RNA- mediated interference (RNAi) pathway. Messenger RNA targets are cleaved by ribonucleases in the RISC complex. In the second mechanism, miRNAs that bind to imperfect complementary sites on messenger RNA transcripts direct gene regulation at the posttranscriptional level but do not cleave their mRNA targets. miRNAs identified in both plants and animals use this mechanism to exert translational control over their gene targets.
- RNAi RNA- mediated interference
- Particular drug candidate compounds are low molecular weight compounds.
- Low molecular weight compounds for example with a molecular weight of 500 Dalton or less, are likely to have good absorption and permeation in biological systems and are consequently more likely to be successful drug candidates than compounds with a molecular weight above 500 Dalton (Lipinski et ah, 2001)).
- Peptides comprise another particular class of drug candidate compounds. Peptides may be excellent drug candidates and there are multiple examples of commercially valuable peptides such as fertility hormones and platelet aggregation inhibitors.
- Natural compounds are another particular class of drug candidate compound. Such compounds are found in and extracted from natural sources, and which may thereafter be synthesized. The lipids are another particular class of drug candidate compound.
- Another preferred class of drug candidate compounds is an antibody.
- the present invention also provides antibodies directed against the TARGETS. These antibodies may be endogenously produced to bind to the TARGETS within the cell, or added to the tissue to bind to the TARGET polypeptide present outside the cell. These antibodies may be monoclonal antibodies or polyclonal antibodies.
- the present invention includes chimeric, single chain, and humanized antibodies, as well as FAb fragments and the products of a FAb expression library, and Fv fragments and the products of an Fv expression library.
- polyclonal antibodies may be used in the practice of the invention.
- the skilled artisan knows methods of preparing polyclonal antibodies.
- Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant.
- the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections.
- Antibodies may also be generated against the intact TARGET protein or polypeptide, or against a fragment, derivatives including conjugates, or other epitope of the TARGET protein or polypeptide, such as the TARGET embedded in a cellular membrane, or a library of antibody variable regions, such as a phage display library.
- the antibodies may be monoclonal antibodies. Monoclonal antibodies may be prepared using methods known in the art.
- the monoclonal antibodies of the present invention may be "humanized” to prevent the host from mounting an immune response to the antibodies.
- a “humanized antibody” is one in which the complementarity determining regions (CDRs) and/or other portions of the light and/or heavy variable domain framework are derived from a non-human immunoglobulin, but the remaining portions of the molecule are derived from one or more human immunoglobulins.
- Humanized antibodies also include antibodies characterized by a humanized heavy chain associated with a donor or acceptor unmodified light chain or a chimeric light chain, or vice versa.
- the humanization of antibodies may be accomplished by methods known in the art (see, e.g. Mark and Padlan, (1994) "Chapter 4. Humanization of Monoclonal Antibodies", The Handbook of Experimental Pharmacology Vol. 1 13, Springer- Verlag, New York). Transgenic animals may be used to express humanized antibodies.
- Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, (1991) J. Mol. Biol. 227:381-8; Marks et al. (1991). J. Mol. Biol. 222:581-97).
- the techniques of Cole, et al. and Boerner, et al. are also available for the preparation of human monoclonal antibodies (Cole, et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77; Boerner, et al (1991). J. Immunol., 147(1):86- 95).
- the antibodies may be monovalent antibodies.
- Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain cross-linking. Alternatively; the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent cross-linking.
- Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens and preferably for a cell-surface protein or receptor or receptor subunit.
- one of the binding specificities is for one domain of the TARGET; the other one is for another domain of the TARGET.
- bispecific antibodies Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy- chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, (1983) Nature 305:537-9). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. Affinity chromatography steps usually accomplish the purification of the correct molecule. Similar procedures are disclosed in Trauneeker, et al. (1991) EMBO J. 10:3655-9.
- a special aspect of the methods of the present invention relates to the down-regulation or blocking of the expression of a TARGET polypeptide by the induced expression of a polynucleotide encoding an intracellular binding protein that is capable of selectively interacting with the TARGET polypeptide.
- An intracellular binding protein includes an activity-inhibitory agent and any protein capable of selectively interacting, or binding, with the polypeptide in the cell in which it is expressed and neutralizing the function of the polypeptide.
- the intracellular binding protein may be an antibody, particularly a neutralizing antibody, or a fragment of an antibody or neutralizing antibody having binding affinity to an epitope of the TARGET polypeptide of SEQ ID NO: 57-112. More particularly, the intracellular binding protein is a single chain antibody.
- the antibodies or a fragments thereof which specifically bind to a TARGET polypeptide and expression inhibiting agents selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), microRNA (miRNA) and a short-hairpin RNA (shRNA) that may be used as therapeutic agents for the treatment of conditions in mammals that are causally related or attributable to fibroblast migration and differentiation.
- a TARGET polypeptide and expression inhibiting agents selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), microRNA (miRNA) and a short-hairpin RNA (shRNA) that may be used as therapeutic agents for the treatment of conditions in mammals that are causally related or attributable to fibroblast migration and differentiation.
- the present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof which specifically binds to a TARGET polypeptide, for use in the treatment of a fibrotic condition.
- a fibrotic condition is a fibrotic condition associated with fibroblast migration and differentiation.
- the present invention provides a method of treating a mammal having, or at risk of having a fibrotic disease, said method comprising administering an effective condition- treating or condition-preventing amount of one or more of the pharmaceutical compositions comprising an antibody or a fragment thereof which specifically binds to a TARGET polypeptide.
- the present invention provides a method of treating a mammal having, or at risk of having idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, bleomycin induced pulmonary fibrosis, chronic asthma, silicosis, asbestos induced pulmonary fibrosis, acute respiratory distress syndrome (ARDS), kidney fibros
- IPF
- the present invention provides an antibody or a fragment thereof which specifically binds to a TARGET polypeptide for use in the treatment, and/or prophylaxis of a fibrotic condition.
- said fibrotic condition is selected from idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug- induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, ble
- IPPF idiopathic
- the present invention provides an antibody or a fragment thereof which specifically binds to a TARGET polypeptide, or a pharmaceutical composition comprising an antibody or a fragment thereof which specifically binds to a TARGET polypeptide for use in the manufacture of a medicament for the treatment, or prophylaxis of a fibrotic condition.
- said fibrotic condition is selected from idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, bleomycin induced pulmonary fibrosis, chronic asthma, silicosis, asbestos induced pulmonary fibrosis, acute respiratory distress syndrome (A DS), kidney fibrosis, tubulointerstitium fibros
- IPF
- a particular regimen of the present method comprises the administration to a subject suffering from a fibrotic disease involving fibroblast migration and differentiation, of an effective amount of an antibody or a fragment thereof which specifically binds to a TARGET polypeptide for a period of time sufficient to reduce the level of abnormal fibrosis in the subject, and preferably terminate the processes responsible for said fibrotic condition.
- a special embodiment of the method comprises administering of an effective amount of an antibody or a fragment thereof which specifically binds to a TARGET polypeptide to a subject patient suffering from or susceptible to the development of a fibrotic disease, for a period of time sufficient to reduce or prevent, respectively, fibrotic condition in said patient, and preferably terminate, the processes responsible for said fibrotic condition.
- said antibody is a monoclonal antibody.
- said antibody is a single chain antibody.
- said fibrotic condition is a fibrotic condition associated with fibroblast migration and differentiation.
- the present invention further relates to compositions comprising said agents, wherein said agent is selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), microRNA (miRNA), and a short-hairpin RNA (shRNA), wherein said agent comprises a nucleic acid sequence complementary to, or engineered from, a naturally- occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-56.
- siRNA small interfering RNA
- miRNA microRNA
- shRNA short-hairpin RNA
- the present invention provides a method of treating a mammal having, or at risk of having a fibrotic disease, said method comprising administering an effective condition- treating or condition-preventing amount of one or more of the pharmaceutical compositions comprising said expression inhibitory agent.
- the present invention provides a method of treating a mammal having, or at risk of having idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug- induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, bleomycin induced pulmonary fibrosis, chronic asthma, silicosis, asbestos induced pulmonary fibrosis, acute respiratory distress syndrome (A DS), kidney idiopathic
- the present invention provides expression inhibitory agents for use in the treatment, and/or prophylaxis of a fibrotic condition.
- said fibrotic condition is selected from idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug- induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, bleomycin induced pulmonary fibrosis, chronic asthma, silico
- the present invention provides expression inhibitory agents, or a pharmaceutical composition comprising said expression inhibitory agents for use in the manufacture of a medicament for the treatment, or prophylaxis of a fibrotic condition.
- said fibrotic condition is selected from idiopathic pulmonary fibrosis (IPF), cystic fibrosis, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma,
- IPPF idiopathic pulmonary
- the compound of the invention for use as a pharmaceutical especially in the treatment and/or prophylaxis of the aforementioned conditions and diseases. Also provided herein is the use of the present compounds in the manufacture of a medicament for the treatment and/or prophylaxis of one of the aforementioned conditions and diseases.
- a particular regimen of the present method comprises the administration to a subject suffering from a fibrotic disease involving fibroblast migration and differentiation, of an effective amount of an expression inhibitory agent for a period of time sufficient to reduce the level of abnormal fibrosis in the subject, and preferably terminate the processes responsible for said fibrotic condition.
- a special embodiment of the method comprises administering of an effective amount of an antibody or a fragment thereof which specifically binds to a TARGET polypeptide to a subject patient suffering from or susceptible to the development of a fibrotic disease, for a period of time sufficient to reduce or prevent, respectively, fibrotic condition in said patient, and preferably terminate, the processes responsible for said fibrotic condition
- said fibrotic condition is a fibrotic condition associated with fibroblast migration and differentiation.
- compositions comprising a DNA expression vector capable of expressing a polynucleotide capable of inhibition of expression of a TARGET polypeptide and described as an expression inhibitory agent.
- the present invention provides compounds, compositions, and methods useful for modulating the expression of the TARGET genes, specifically those TARGET genes associated with a fibrotic disease and for treating such conditions by RNA interference (RNAi) using small nucleic acid molecules.
- RNAi RNA interference
- the instant invention features small nucleic acid molecules, i.e., short interfering nucleic acid (siNA) molecules including, but not limited to, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA) and circular RNA molecules and methods used to modulate the expression of the TARGET genes and/or other genes involved in pathways of the TARGET gene expression and/or activity.
- siNA short interfering nucleic acid
- siRNA short interfering RNA
- dsRNA double-stranded RNA
- miRNA micro-RNA
- shRNA short hairpin RNA
- compositions and methods relate to the down-regulation or blocking of the expression of the TARGET by the induced expression of a polynucleotide encoding an intracellular binding protein that is capable of selectively interacting with the TARGET.
- An intracellular binding protein includes any protein capable of selectively interacting, or binding, with the polypeptide in the cell in which it is expressed and neutralizing the function of the polypeptide.
- the intracellular binding protein is a neutralizing antibody or a fragment of a neutralizing antibody having binding affinity to an epitope of a TARGET selected from the group consisting of SEQ ID NO: 57-112. More preferably, the intracellular binding protein is a single chain antibody.
- Antibodies according to the invention may be delivered as a bolus only, infused over time or both administered as a bolus and infused over time.
- Those skilled in the art may employ different formulations for polynucleotides than for proteins.
- delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
- a particular embodiment of this composition comprises the expression-inhibiting agent selected from the group consisting of antisense RNA, antisense oligodeoxynucleotide (ODN), a ribozyme that cleaves the polyribonucleotide coding for a TARGET selected from the group consisting of SEQ ID NO: 1-56, a small interfering RNA (siRNA), and a microRNA that is sufficiently homologous to a portion of the polyribonucleotide coding for a TARGET selected from the group consisting of SEQ ID NO: 1-56, such that the siRNA or microRNA interferes with the translation of the TARGET polyribonucleotide to the TARGET polypeptide.
- ODN antisense oligodeoxynucleotide
- a ribozyme that cleaves the polyribonucleotide coding for a TARGET selected from the group consisting of SEQ ID NO: 1-56
- siRNA small interfering
- the polynucleotide expressing the expression-inhibiting agent, or a polynucleotide expressing the TARGET polypeptide in cells is particularly included within a vector.
- the polynucleic acid is operably linked to signals enabling expression of the nucleic acid sequence and is introduced into a cell utilizing, preferably, recombinant vector constructs, which will express the antisense nucleic acid once the vector is introduced into the cell.
- viral-based systems including adenoviral, retroviral, adeno-associated viral, lentiviral, herpes simplex viral or a sendaiviral vector systems, and all may be used to introduce and express polynucleotide sequence for the expression- inhibiting agents or the polynucleotide expressing the TARGET polypeptide in the target cells.
- the viral vectors used in the methods of the present invention are replication defective.
- Such replication defective vectors will usually pack at least one region that is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), or be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution, partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed in vitro (on the isolated DNA) or in situ, using the techniques of genetic manipulation or by treatment with mutagenic agents.
- the replication defective virus retains the sequences of its genome, which are necessary for encapsidating, the viral particles.
- the viral element is derived from an adenovirus.
- the vehicle includes an adenoviral vector packaged into an adenoviral capsid, or a functional part, derivative, and/or analogue thereof.
- Adenovirus biology is also comparatively well known on the molecular level. Many tools for adenoviral vectors have been and continue to be developed, thus making an adenoviral capsid a preferred vehicle for incorporating in a library of the invention.
- An adenovirus is capable of infecting a wide variety of cells. However, different adenoviral serotypes have different preferences for cells.
- the vehicle includes adenoviral fiber proteins from at least two adenoviruses.
- Preferred adenoviral fiber protein sequences are serotype 17, 45 and 51. Techniques or construction and expression of these chimeric vectors are disclosed in US 2003/0180258 and US 2004/0071660, hereby incorporated by reference.
- the nucleic acid derived from an adenovirus includes the nucleic acid encoding an adenoviral late protein or a functional part, derivative, and/or analogue thereof.
- An adenoviral late protein for instance an adenoviral fiber protein, may be favorably used to target the vehicle to a certain cell or to induce enhanced delivery of the vehicle to the cell.
- the nucleic acid derived from an adenovirus encodes for essentially all adenoviral late proteins, enabling the formation of entire adenoviral capsids or functional parts, analogues, and/or derivatives thereof.
- the nucleic acid derived from an adenovirus includes the nucleic acid encoding adenovirus E2A or a functional part, derivative, and/or analogue thereof.
- the nucleic acid derived from an adenovirus includes the nucleic acid encoding at least one E4-region protein or a functional part, derivative, and/or analogue thereof, which facilitates, at least in part, replication of an adenoviral derived nucleic acid in a cell.
- the adenoviral vectors used in the examples of this application are exemplary of the vectors useful in the present method of treatment invention.
- Retroviral vector systems are integrating viruses that infect dividing cells, and their construction is known in the art. Retroviral vectors can be constructed from different types of retrovirus, such as, MoMuLV ("murine Moloney leukemia virus”) MSV ("murine Moloney sarcoma virus”), HaSV ("Harvey sarcoma virus”); SNV ("spleen necrosis virus”); RSV ("Rous sarcoma virus”) and Friend virus. Lentiviral vector systems may also be used in the practice of the present invention.
- adeno-associated viruses are utilized.
- the AAV viruses are DNA viruses of relatively small size that integrate, in a stable and site-specific manner, into the genome of the infected cells. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies.
- recombinant viruses may be used to introduce DNA encoding polynucleotide agents useful in the present invention.
- Recombinant viruses according to the invention are generally formulated and administered in the form of doses of between about 104 and about 1014 pfu. In the case of AAVs and adenoviruses, doses of from about 106 to about 101 1 pfu are particularly used.
- pfu plaque-forming unit
- plaque-forming unit corresponds to the infective power of a suspension of virions and is determined by infecting an appropriate cell culture and measuring the number of plaques formed. The techniques for determining the pfu titre of a viral solution are well documented in the prior art.
- the polynucleotide agents of the present invention may be linked to one or more regulatory regions. Selection of the appropriate regulatory region or regions is a routine matter, within the level of ordinary skill in the art. Regulatory regions include promoters, and may include enhancers, suppressors, etc.
- Promoters that may be used in the expression vectors of the present invention include both constitutive promoters and regulated (inducible) promoters.
- the promoters may be prokaryotic or eukaryotic depending on the host.
- prokaryotic (including bacteriophage) promoters useful for practice of this invention are lac, lacZ, T3, T7, lambda P r , Pi, and trp promoters.
- eukaryotic (including viral) promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), therapeutic gene promoters (e.g.
- tissue-specific promoters including animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals, e.g. chymase gene control region which is active in mast cells (Liao et al, (1997), Journal of Biological Chemistry, 272, : 2969-2976), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl, et al. (1984) Cell 38:647-58; Adames, et al. (1985) Nature 318:533-8; Alexander, et al. (1987) Mol. Cell. Biol.
- mice mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells
- beta-globin gene control region which is active in myeloid cells
- CMV promoter and the Visna LTR are preferentially activated in dividing cells
- promoters which respond to a stimulus e.g.
- promoters which may be of use in the practice of the invention include promoters which are active and/or expressed in macrophages or other cell types contributing to inflammation such as dendritic cells, monocytes, neutrophils, mast cells, endothelial cells, epithelial cells, muscle cells, etc..
- Additional vector systems include the non- viral systems that facilitate introduction of polynucleotide agents into a patient.
- a DNA vector encoding a desired sequence can be introduced in vivo by lipofection.
- Synthetic cationic lipids designed to limit the difficulties encountered with liposome-mediated transfection can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Feigner, et. al. (1987) Proc. Natl. Acad Sci. USA 84:7413- 7); see Mackey, et al. (1988) Proc. Natl. Acad. Sci. USA 85:8027-31 ; Ulmer, et al. (1993) Science 259:1745-8).
- cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Feigner and Ringold, (1989) Nature 337:387-8).
- Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO 95/18863 and WO 96/17823, and in U.S. Pat. No. 5,459,127.
- the use of lipofection to introduce exogenous genes into the specific organs in vivo has certain practical advantages and directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, for example, pancreas, liver, kidney, and the brain.
- Lipids may be chemically coupled to other molecules for the purpose of targeting.
- Targeted peptides e.g., hormones or neurotransmitters, and proteins for example, antibodies, or non-peptide molecules could be coupled to liposomes chemically.
- Other molecules are also useful for facilitating transfection of a nucleic acid in vivo, for example, a cationic oligopeptide (e.g., International Patent Publication WO 95/21931), peptides derived from DNA binding proteins (e.g., International Patent Publication WO 96/25508), or a cationic polymer (e.g., International Patent Publication WO 95/21931).
- DNA vector in vivo as a naked DNA plasmid (see U.S. Pat. Nos. 5,693,622, 5,589,466 and 5,580,859).
- naked DNA vectors for therapeutic purposes can be introduced into the desired host cells by methods known in the art, e.g., transfection, electr op oration, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (see, e.g., Wilson, et al. (1992) J. Biol. Chem. 267:963-7; Wu and Wu, (1988) J. Biol. Chem.
- a biologically compatible composition is a composition, that may be solid, liquid, gel, or other form, in which the compound, polynucleotide, vector, and antibody of the invention is maintained in an active form, e.g., in a form able to effect a biological activity.
- a compound of the invention would have inverse agonist or antagonist activity on the TARGET; a nucleic acid would be able to replicate, translate a message, or hybridize to a complementary mRNA of the TARGET; a vector would be able to transfect a target cell and express the antisense, antibody, ribozyme or siRNA as described hereinabove; an antibody would bind a the TARGET polypeptide domain.
- a particular biologically compatible composition is an aqueous solution that is buffered using, e.g., Tris, phosphate, or HEPES buffer, containing salt ions. Usually the concentration of salt ions will be similar to physiological levels.
- Biologically compatible solutions may include stabilizing agents and preservatives.
- the biocompatible composition is a pharmaceutically acceptable composition.
- Such compositions can be formulated for administration by topical, oral, parenteral, intranasal, subcutaneous, and intraocular, routes. Parenteral administration is meant to include intravenous injection, intramuscular injection, intraarterial injection or infusion techniques.
- the composition may be administered parenterally in dosage unit formulations containing standard, well-known non-toxic physiologically acceptable carriers, adjuvants and vehicles as desired.
- compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
- Pharmaceutical compositions for oral use can be prepared by combining active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl- cellulose, or sodium carboxymethyl-cellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen.
- disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
- Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinyl-pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinyl-pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
- compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
- Push-fit capsules can contain active ingredients mixed with filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
- Particular sterile injectable preparations can be a solution or suspension in a non-toxic parenterally acceptable solvent or diluent.
- pharmaceutically acceptable carriers are saline, buffered saline, isotonic saline (for example, monosodium or disodium phosphate, sodium, potassium; calcium or magnesium chloride, or mixtures of such salts), Ringer's solution, dextrose, water, sterile water, glycerol, ethanol, and combinations thereof 1,3-butanediol and sterile fixed oils are conveniently employed as solvents or suspending media. Any bland fixed oil can be employed including synthetic mono- or di-glycerides. Fatty acids such as oleic acid also find use in the preparation of injectables.
- the compounds or compositions of the invention may be combined for administration with or embedded in polymeric carrier(s), biodegradable or biomimetic matrices or in a scaffold.
- the carrier, matrix or scaffold may be of any material that will allow composition to be incorporated and expressed and will be compatible with the addition of cells or in the presence of cells. Particularly, the carrier matrix or scaffold is predominantly non-immunogenic and is biodegradable.
- biodegradable materials include, but are not limited to, polyglycolic acid (PGA), polylactic acid (PLA), hyaluronic acid, catgut suture material, gelatin, cellulose, nitrocellulose, collagen, albumin, fibrin, alginate, cotton, or other naturally- occurring biodegradable materials.
- the matrix or scaffold material may be sterilized prior to administration or implantation, e.g., by treatment with ethylene oxide or by gamma irradiation or irradiation with an electron beam.
- a number of other materials may be used to form the scaffold or framework structure, including but not limited to: nylon (polyamides), dacron (polyesters), polystyrene, polypropylene, polyacrylates, polyvinyl compounds (e.g., polyvinylchloride), polycarbonate (PVC), polytetrafluorethylene (PTFE, teflon), thermanox (TPX), polymers of hydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), and polylactic acid-glycolic acid (PLGA), polyorthoesters, polyanhydrides, polyphosphazenes, and a variety of polyhydroxyalkanoates, and combinations thereof.
- nylon polyamides
- dacron polymers
- polystyrene polyprop
- Matrices suitable include a polymeric mesh or sponge and a polymeric hydrogel.
- the matrix is biodegradable over a time period of less than a year, more particularly less than six months, most particularly over two to ten weeks.
- the polymer composition, as well as method of manufacture, can be used to determine the rate of degradation. For example, mixing increasing amounts of polylactic acid with polyglycolic acid decreases the degradation time.
- Meshes of polyglycolic acid that can be used can be obtained commercially, for instance, from surgical supply companies (e.g., Ethicon, N.J). In general, these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof.
- the composition medium can also be a hydrogel, which is prepared from any biocompatible or non-cytotoxic homo- or hetero-polymer, such as a hydrophilic polyacrylic acid polymer that can act as a drug absorbing sponge. Certain of them, such as, in particular, those obtained from ethylene and/or propylene oxide are commercially available.
- a hydrogel can be deposited directly onto the surface of the tissue to be treated, for example during surgical intervention.
- Embodiments of pharmaceutical compositions of the present invention comprise a replication defective recombinant viral vector encoding the agent of the present invention and a transfection enhancer, such as poloxamer.
- a poloxamer is Poloxamer 407, which is commercially available (BASF, Parsippany, N.J.) and is a non-toxic, biocompatible polyol.
- a poloxamer impregnated with recombinant viruses may be deposited directly on the surface of the tissue to be treated, for example during a surgical intervention. Poloxamer possesses essentially the same advantages as hydrogel while having a lower viscosity.
- the active agents may also be entrapped in microcapsules prepared, for example, by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, for example, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl- methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
- copolymers of L- glutamic acid and gamma-ethyl-L-glutamate non-degradable ethylene-vinyl acetate
- degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM. (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
- encapsulated antibodies When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio- disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
- therapeutically effective dose means that amount of protein, polynucleotide, peptide, or its antibodies, agonists or antagonists, which ameliorate the symptoms or condition.
- Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population).
- the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 50 /ED 50 .
- Pharmaceutical compositions that exhibit large therapeutic indices are particular.
- the data obtained from cell culture assays and animal studies are used in formulating a range of dosage for human use.
- the dosage of such compounds lies particularly within a range of circulating concentrations that include the ED 50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
- the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs.
- the animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- the exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state, age, weight and gender of the patient; diet, desired duration of treatment, method of administration, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
- compositions according to this invention may be administered to a subject by a variety of methods. They may be added directly to targeted tissues, complexed with cationic lipids, packaged within liposomes, or delivered to targeted cells by other methods known in the art. Localized administration to the desired tissues may be done by direct injection, transdermal absorption, catheter, infusion pump or stent.
- the DNA, DNA/vehicle complexes, or the recombinant virus particles are locally administered to the site of treatment.
- Alternative routes of delivery include, but are not limited to, intravenous injection, intramuscular injection, subcutaneous injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. Examples of ribozyme delivery and administration are provided in Sullivan et al. WO 94/02595.
- Administration of an expression- inhibiting agent or an antibody of the present invention to the subject patient includes both self-administration and administration by another person.
- the patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk for diseases and medical conditions affected by differentiation of macrophages into alternatively-activated macrophages.
- the expression-inhibiting agent of the present invention may be delivered to the subject patient orally, transdermally, via inhalation, injection, nasally, rectally or via a sustained release formulation. IN VITRO METHODS
- the present invention also provides an in vitro method of inhibiting fibroblast migration and differentiation, said method comprising contacting a population of fibroblasts with an inhibitor of the activity or expression of a TARGET polypeptide.
- said inhibitor is an antibody.
- said antibody is a monoclonal antibody.
- the present invention further relates to an in vitro method of inhibiting fibroblast migration and differentiation, said method comprising contacting a population of fibroblasts with an inhibitor selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), microRNA (miRNA) and a short-hairpin RNA (shRNA), wherein said inhibitor comprises a nucleic acid sequence complementary to, or engineered from, a naturally- occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid encoding a TARGET polypeptide.
- an inhibitor selected from the group consisting of an antisense polynucleotide, a ribozyme, a small interfering RNA (siRNA), microRNA (miRNA) and a short-hairpin RNA (shRNA)
- said inhibitor comprises a nucleic acid sequence complementary to, or engineered from, a naturally
- Antisense nucleic acids of the invention are particularly nucleic acid fragments capable of specifically hybridizing with all or part of a nucleic acid encoding a TARGET polypeptide or the corresponding messenger RNA.
- antisense nucleic acids may be designed which decrease expression of the nucleic acid sequence capable of encoding a TARGET polypeptide by inhibiting splicing of its primary transcript. Any length of antisense sequence is suitable for practice of the invention so long as it is capable of down-regulating or blocking expression of a nucleic acid coding for a TARGET.
- the antisense sequence is at least about 15-30, and particularly at least 17 nucleotides in length.
- the preparation and use of antisense nucleic acids, DNA encoding antisense RNAs and the use of oligo and genetic antisense is known in the art.
- Example 1 describes the fibroblast scratch screening assay and primary screen using custom adenoviral library.
- Example 2 describes the re-screen of identified hits in of the example lusing fibroblast scratch assay.
- Example 3 describes the fibroblast-to-myofibroblast transition (FMT) validation assay.
- Example 4 describes the "On-target” analysis
- Example 5 describes viability assay.
- Example 6 describes whole transcriptome sequencing.
- Example 1. Fibroblast scratch assay
- Migrating fibroblasts are considered to play a major role in the pathology of idiopathic pulmonary fibrosis.
- the fibroblast scratch assay is a wound healing assay that is a measure for cell motility and migration.
- the propensity of lung fibroblasts to close an open wound in a cell monolayer is considered to predict their contribution to idiopathic pulmonary fibrosis.
- the cells are routinely cultured and expanded in Dulbecco' s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS) and penicillin- streptomycin at 37°C, 5% CO 2 in a humidified atmosphere.
- DMEM Dulbecco' s Modified Eagle Medium
- HI-FBS heat-inactivated fetal bovine serum
- penicillin- streptomycin 37°C, 5% CO 2 in a humidified atmosphere.
- FIG. 1 shows examples of algorithm-based segmentation of an open and closed fibroblast scratch wound.
- the segmentation indicated in the segmentation figures is based on the maximal open area of the scratch in images of rhodamin-phalloidin stained cells, and the nuclei based on DAPI staining of the nuclei.
- the maximal open area is defined as the largest open area within a mechanical scratch wound in a fibroblast monolayer.
- the rhodamin-phalloidin-based segmentation was used to quantify the maximal open area in the fibroblast scratch assay.
- This algorithm allowed the measurement of two parameters: i) total open area which is the sum of all segmented areas, and ii) maximal open area (further referred to as max open area), which only includes the largest open area.
- the max open area parameter has the advantage that intercellular spaces that are formed upon migration of cells are excluded, but may have the risk of losing part of the total open area due to separation of an open area by migrating cells. Therefore, measurement of the max open area was used as a measure of wound closure.
- triggers can be used at different time points (pre- or post- scratch).
- a skilled person would be aware of a number of such possible triggers.
- These triggers can be IL-13, CCL21, CTGF and PDGF-BB in the presence or absence of fetal bovine serum (FBS).
- FBS contains multiple growth stimulation factors.
- Each 96-well plate contained 2 negative control shRNAs, one against a non-expressed gene (luciferase; luc_vl3) and one against the murine nitric oxide synthase gene (mmNos_v3).
- a "no virus”control was used as a negative control.
- 5 positive (PIK3 C3_v3 , CXCPv4_vl4, PDGFRA_vl2, COLlAl_v5, and PGKl_v2) controls were also used and the summary of the controls is presented in Table 3.
- Table 3 Overview of positive and negative controls used in the primary screen.
- PDGF-BB is a growth factor and may therefore not only induce migration but also subsequent cell proliferation.
- the time frame cells were allowed to migrate into a scratched wound was limited to 20 h and hence PDGF-BB and/or FBS induced migration may not yet be enhanced.
- cell numbers were counted in areas surrounding the scratches. Comparing nuclear counts in these areas under triggered and un-triggered conditions confirmed that no significant increase was observed and thus no enhanced proliferation took place in the first 16 h after scratching. Transduction of the cells prior to scratching results in a slight decrease in cell number. This decrease appears to be a general adenoviral effect regardless of the shRNA construct the virus contains.
- the primary screen the normal human lung fibroblast donor FB0054 at passage three was selected.
- the primary screen was performed using over >12,000 adenoviral shRNA constructs from in-house adenoviral library.
- the full screen consisted of 140 x 96-well plates and was performed in biological duplicate.
- the assay setup for the primary screen was under the following conditions:
- the IQR method uses the median (Q2) and inter quartile range (Q3-Q1) as a measure for data dispersion.
- Q1-Q2 median and inter quartile range
- Q3-Q1 inter quartile range
- the choice of cut-off determines the error rate (probability of identifying a non-hit as a hit). Therefore, for hit calling, an IQR method was used with IQR3 as a measure of sample distribution (median and Q3- Q2).
- the 1074 unique viruses which were identified as a hit in the primary screen, were re- propagated for the rescreen phase.
- the rescreen was performed using similar test conditions as in the primary screen (Example 1), but in a different donor in order to eliminate donor specific effects of viruses.
- the NHLF donor 99218 (passage four) was used, and seeded at a concentration of 3000 cells / well.
- hit calling in the rescreen would be based on negative controls. Therefore at least 30% of the 96 wells in each plate consisted of negative controls.
- five positive controls were included in column seven. The identity of the control set is listed in Table 4.
- Hit identification on rescreen data was performed using the Robust Z-score based on negatives.
- the "Robust Z-score method” combines negative control measurements altogether under the assumption that they are inactive and serve as controls, taken into account outlier values in order to minimize their undesirable influence (Malo et al. 2006). A separation between positive and negative controls was observed, with P3 being the strongest inhibitor, and P2, P4, and P5 being moderate inhibitors of wound healing.
- Myofibroblasts are considered to play a major role in the pathology of idiopathic pulmonary fibrosis.
- the fibroblast-to-myofibroblast transition (FMT) assay using a-smooth muscle actin (aSMA) as read-out, enables high throughput identification of genes involved in the myofibroblast differentiation of lung-derived fibroblasts.
- FMT fibroblast-to-myofibroblast transition
- ASMA smooth muscle actin
- Trigger was added in DMEM supplemented with 0.2 % HI-FBS. The cells were triggered with 0.5 ng/mL TGFp for 72 hrs. The most optimal window between triggered and non-triggered cells was observed using this concentration of the trigger.
- aSMA in fibroblasts undergoing FMT in response to TGF was measured by high content imaging on an InCell200 instrument (GE Healthcare) following immune staining with mouse-anti-human aSMA, followed by donkey-anti-mouseAlexa546, and DAPI, and subsequently analyzed using an in-house developed algorithm with InCell developer software (GE Healthcare).
- the segmentation indicated in the segmentation images of Figure 4 is based on the staining of aSMA, and the nuclei based on DAPI staining.
- the aSMA-based segmentation was used to identify the myofibroblasts in the image.
- the density times the stained area was used to quantify the aSMA expression in the image, which is a measure for FMT.
- a clear increase in aSMA positive cells was observed for fibroblasts triggered with TGFB as compared to the no trigger condition, whereas no difference was observed in the number of nuclei between non-triggered and triggered conditions.
- Reference source not founcL Figure 4 shows the principles of the algorithm-based segmentation.
- the red lines indicate the segmentation based on DAPI staining of the nuclei, while the green lines indicate segmentation based on images of aSMA staining. These images clearly showed that the green lines closely align with the aSMA positive cells and hence this aSMA-based segmentation was use in data analysis.
- Table 6 Contents of control set.
- the set-up of the FMT screening protocol is presented in Figure 5.
- the complete validation assay was performed in the normal human lung fibroblast donor FB0202 (passage three).
- the cells were seeded at a concentration of 3000 cells / well on PureCol-coated 96-well plates.
- On day one cells were transduced with the 216 shRNA carrying viruses from the fibroblast wound assay rescreen (Example 2).
- On three plates a well with non-transduced cells was taken along in order to monitor the general virus effect on the aSMA expression.
- the aSMA expression was determined using high content imaging and subsequently quantified using the above-described algorithm (see 3.3).
- the on target analysis was performed using similar test conditions as in the primary screen (Example 1), in the same normal human fibroblast donor FB0054 (passage three). For each of the 116 candidate Targets from Example 3, at least five additional constructs were designed, produced, and re- propagated.
- NHLF cells from donor FB0054 were seeded at a density of 3000 cells per well and subsequently transduced. Cells were then triggered with 0.2%> HI-FBS plus 50 ng/mL PDGF-BB and the maximum open area was measured. MOI of 18 was used for the viral transduction, and the optimal timing for the measurement of wound closure was set at 12 h.
- CTB CellTiter Blue
- the CTB assay is based on the ability of living cells to convert resazurin (a redox dye) into resorufin (a fluorescent end product). Nonviable cells rapidly lose metabolic capacity and thus do not generate a fluorescent signal. As a reference for cytotoxicity, a serial dilution of staurosporin was taken along on each plate. Loss of cells is indicative for toxicity and therefore nuclear count was used to assess cytotoxicity.
- the assay setup was the same as for the "on target" screen (see Example 4) and a schematic overview is depicted in Figure 8.
- the fluorescence measurement of CTB was performed 24 hrs after addition of a solution containing resazurin. To identify viruses inducing toxicity, CTB fluorescence levels of individual viruses were compared with the average of the negative controls. Viruses demonstrating CTB values that are lower than 70% of the negative control average were considered toxic and were therefore excluded.
- mRNA-seq is a cDNA sequencing application that can be used to profile the entire mRNA population and that enables mapping and quantification of all transcripts. With no probes or primer design needed, mRNA-seq has the potential to provide relatively unbiased sequence information from polyA-tailed RNA for analysis of gene expression, novel transcripts, novel isoforms, alternative splice sites, and rare transcripts in a single experiment, depending on read depth.
- FIB-202-U For the untriggered sample (FIB-202-U), cells of two 96-well plates were harvested 24 hrs after seeding for RNA isolation. Two other 96-well plates were triggered (FIB-202-T) with 0.2% Hi-FCS and 0.5 ng/mL TGF , five days after seeding. The cells were triggered for 72 hrs, and were subsequently harvested for RNA isolation.
- RNA sample(s) was analyzed on a RNA 6000 Lab-on-a-Chip using the Bioanalyzer 2100 (Agilent Technologies). Sample quality met the requirements for sample preparation.
- the Illumina® mRNA-Seq Sample Prep Kit was used to process the samples. The sample preparation was performed according to the Illumina protocol "Preparing Samples for Sequencing of mRNA" (1004898 Rev. D). Briefly, mRNA was isolated from total RNA using the poly-T-oligo-attached magnetic beads. After fragmentation of the mRNA, cDNA synthesis was performed. This was used for ligation with the sequencing adapters and PCR amplification of the resulting product.
- Image analysis, base-calling, and quality check was performed with the Illumina data analysis pipeline RTA vl .13.48 and/or OLB vl .9 and CASAVA vl .8.2.
- QA analysis performed to evaluate the quality of an Illumina sequencing run was based on quality metrics for a standard run of good quality using the Solexa technology. All lanes of the flow cell passed the QA analysis. Additionally, detailed error rate information based on an Illumina supplied Phi X control was reported. The Phi X control is spiked into the sample in a small amount (up to 5% of the reads). The reads from the Illumina control DNA are removed by the Illumina pipeline during processing of the data. The error rate is calculated after alignment of the reads passing the quality filter to the Phi X reference genome using the ELAND aligner in the Illumina pipeline. All error rates were within the allowed criteria.
- Reads obtained from the Illumina HiSeq 2000 sequencer were filtered by quality scores with a minimum threshold of Q25 and minimum length of 50 bases. Reads were then aligned to the human reference genome (hgl9) with the Bowtie vO.12.7 aligner for each sample. New isoforms were identified with the Cufflinks v2.02 package using default settings and the known transcriptome annotation as mask (Homo_sapiens.GRCh37.65.gff).
- the newly detected isoforms were merged for all samples and added to the standard t r a n s c r i p t o m e a n n o t a t i o n .
- F i n a l l y , F P K M ( F r a g m e n t s Per Kilobase of transcript per Million fragments mapped) values were calculated with Cufflinks for each sample and reported in the default Cufflinks output.
- the FPKM values are a quantitative representation of the mRNAs in the samples and therefore in the cells used for the mRNA-seq analysis and the screening assays. Highly abundant mRNAs result in high FPKM values whereas low FPKM values represent low copy numbers of the mRNA.
- siRNA against ACTA2, SMAD3, SMAD4, TGFBR1 and TGFBR2 were used as positive controls and non-targeting siRNA (Thermo Fisher Scientific Biosciences GMBH) was used as a negative control.
- the experimental setup was as follows: On day 0 3000 cells/well of normal human lung fibroblast were seeded in 96-well plates with 3.2 ⁇ g/mL PureCol coating (Advanced Biomatrix Cat# 5005-B). Three days later the siRNA transfection was preformed. Cells were transfected using 0.02 ⁇ ⁇ of Dharmafect 1 (Thermo, Cat # T-2001-03). OnTarget Plus siRNA (Thermo Fisher Scientific Biosciences GMBH) in the final concentration of 20 nM were used as smart pools of 4 constructs per well. For RHBDL2 each siRNA construct was also tested individually. One day after medium was refreshed.
- RNA isolation was performed using standard MagMax Total RNA isolation kit (Ambion, Cat # AMI 830). a-SMA staining and measurement was performed on day 8.
- aSMA in fibroblasts undergoing FMT in response to TGF was measured by high content imaging on an InCell200 instrument (GE Healthcare) following immuno staining with mouse-anti-human aSMA, followed by donkey-anti-mouse Alexa546, and DAPI, and subsequently analyzed using an in-house developed algorithm with InCell developer software (GE Healthcare). Nuclei count was used as a quality control.
- NPI Normalized percentage inhibition
- FMT fibroblast-to-myofibroblast transition
- ASMA smooth muscle actin
- Table 7 Contents of the control set.
- NHLF cells from donor FB0054 were seeded at a density of 3000 cells per well in 96-well plates coated with 32 ⁇ g/mL PureCol in 2% FBS-DMEM. Cells were transduced one day later. MOI of 18 was used for the viral transduction. One day after transduction the medium was refreshed. On day 6 the cells were triggered using 2 ng/mL TGF -l in 2% FBS-DMEM. On day 7 a dilution range of Staurosporin was added to the control wells (one column per plate). The Staurosporin treatment was performed for around 20 hours, whereby plates were incubated at 37°C at 5% CO 2 . On day 8 the supernatant was harvested and the cells were fixed. For fixing, 4% formaldehyde was added to the cells, incubated for 30 min at room temperature and subsequently replaced by PBS (Gibco Cat # 10010).
- aSMA in fibroblasts undergoing FMT in response to TGF -l was measured by high content imaging on an InCell200 instrument (GE Healthcare) following immune staining with mouse-anti-human aSMA, followed by donkey-anti-mouseAlexa546, and DAPI, and subsequently analyzed using an in-house developed algorithm with InCell developer software (GE Healthcare). The same protocol was used as desfribed in the Example 3.
- Normalized percentage inhibition (NPI) analysis was used to quantify the effect of shRNA constructs on the read-out. Average measurements of ACTA2_v4 values were used as a positive control and the values mmNos3_v3 negative control were used in the calculations. Normalized percentage inhibition (NPI) was calculated by dividing the difference between sample measurements and the average of positive controls through the difference between positive and negative controls. A construct demonstrating at least 40% inhibition on that scale was considered "on-target".
- shRNA constructs against two specific targets were tested: PTGIR and RHBDL2 . At least 2 shRNA constructs against PTGIR and RHBDL2 targets showed significant levels of inhibition with PTGIR having all 5 constructs demonstrating more than 40% inhibition of aSMA production and 4 out of 9 constructs against RHBDL2 demonstrating at least 40% inhibition.
- Example 9 TARGET expression in animal models of fibrosis
- mice Unilateral ureteral obstruction was performed on Balb/c female mice (from Harlan-France), with 10 mice/group. On day 0, mice were anaesthetized by intra-peritoneal injection and after incision of the skin, the left ureter was dissected out and ligatured with 4.0 silk at two points along its length. The ureter was then sectioned between the 2 ligatures. Intact mice were used as control. Mice were sacrificed by exsanguinations with scissors under anaesthesia after 10 or 21 days.
- Nephrectomy was performed on Sprague-Dawley male rats (from CERJ-France), with 10 rats/group. At DayO, rats were anaesthetized and after incision of the skin, the kidney capsule was removed while preserving the adrenal gland. The renal hilum was ligated and right kidney was removed. The ends of the left kidney are cut with a scalpel resulting in 5/6 nephrectomy. Rats were sacrificed after 4 or 8 weeks.
- mice/group administration with 6 to 8 mice/group and on C57/B16 J female mice (from Janvier) for bleomycin i.t. administration with 14 mice/group.
- mice were injected intravenously (i.v.) with bleomycin (10 mg/kg; ⁇ /mouse) or saline as a control once per day for the first five consecutive days (Oku et al., 2004). Mice were sacrificed by exsanguinations with scissors under anaesthesia after 3 or 6 weeks.
- mice were anaesthetized by intra-peritoneal injection (under a volume of lOmL/kg) of anaesthetic solution (18mL NaCl 0.9% + 0.5mL xylazine (5mg/kg) + 1.5mL ketamine (75mg/kg)).
- Bleomycin solution at 2U/kg or saline was administered by intratracheal route (10 mg/kg; 40 ⁇ / ⁇ 86). Mice were sacrificed by exsanguinations with scissors under anaesthesia after 3 weeks.
- mice were anesthetised by intra-peritoneal injection of a solution (Xylazine 5mg/kg, ketamine 75mg/kg) and shaved. A volume of ⁇ of bleomycin solution at lmg/ml or saline was injected subcutaneously with a 26g needle into the shaved backs of mice. Bleomycin was injected 5 days per week for 3 consecutive weeks. The total experimental period was 6 weeks. Mice were sacrificed by exsanguinations with scissors under anaesthesia after 6 weeks.
- Table 11 Overview of the performance of fibroblast TARGETS in the primary screen, rescreen, and FMT validation assay.
- This table gives an overview of the performance of the TARGETS.
- the first column shows the gene symbol of the corresponding target.
- Duplicate IQR-scores are shown for the primary fibroblast scratch screen, where a cut-off of IQR > 1.5 was used and rescreen where a cut-off of robustZ > 1.2 was used.
- Results of the FMT validation assay are shown with duplicate Z-scores where a cut-off of robustZ ⁇ -1.8 was used.
- Table 12 Overview of the performance of the shRNA contructs against the TARGETS in the on-target validation.
- the confirmed candidate TARGET gene name and knock-down sequence of the adenoviral constructs are shown.
- Results for the shRNAs which were considered a hit are shown and in addition the shRNA that originally was a hit (bold), and the "O.H.” column shows if this shRNA was a hit again in both on-target (OT) assays (Yes/ No).
- Duplicate results are shown for the fibroblast scratch on target screen with a cut-off of RobustZ > 1.5.
- CTB results and nuclei count results are shown as duplicate RobustZ.
- Table 13 Overview of the expression of the TARGETS in on target analysis.
- the confirmed candidate Target Gene Symbols are shown with the corresponding gene class of the Target.
- Expression data is shown as EST per Million in lungs.
- Expression data obtained from RNA- seq is shown as an FPKM value of one normal human fibroblast donor, either non-triggered or triggered with TGF .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
L'invention concerne des méthodes et des dosages permettant d'identifier des agents utilisés pour le traitement de la fibrose, en particulier les maladies associées à la migration et à la différenciation des fibroblastes. L'invention propose des CIBLES de polypeptides et d'acides nucléiques, des séquences d'ARNsi basées sur ces CIBLES et des anticorps dirigés contre les CIBLES. L'invention concerne également une composition pharmaceutique comprenant des séquences d'ARNsi basées sur les CIBLES et des anticorps dirigés contre les CIBLES utilisés dans le cadre du traitement de la fibrose. L'invention concerne par ailleurs des méthodes in vitro permettant d'inhiber la migration et la différenciation des fibroblastes.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14708866.0A EP2972380A2 (fr) | 2013-03-14 | 2014-03-07 | Cibles et composés moléculaires destinés au traitement de la fibrose, et méthodes utilisées pour les identifier |
US14/775,828 US9952202B2 (en) | 2013-03-14 | 2014-03-07 | Methods of identifying compounds for the treatment of fibrosis by using S1PR5 |
JP2015562042A JP2016518812A (ja) | 2013-03-14 | 2014-03-07 | 線維症治療において有用な分子標的及び前記標的のインヒビター |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361781473P | 2013-03-14 | 2013-03-14 | |
US61/781,473 | 2013-03-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014139884A2 true WO2014139884A2 (fr) | 2014-09-18 |
WO2014139884A3 WO2014139884A3 (fr) | 2014-12-31 |
Family
ID=50239628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/054442 WO2014139884A2 (fr) | 2013-03-14 | 2014-03-07 | Cibles et composés moléculaires destinés au traitement de la fibrose, et méthodes utilisées pour les identifier |
Country Status (4)
Country | Link |
---|---|
US (1) | US9952202B2 (fr) |
EP (1) | EP2972380A2 (fr) |
JP (1) | JP2016518812A (fr) |
WO (1) | WO2014139884A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110128535A (zh) * | 2019-03-27 | 2019-08-16 | 浙江工业大学 | 一种amh单克隆抗体及其制备与应用 |
US20230088277A1 (en) * | 2020-01-23 | 2023-03-23 | Junling Liu | Related target for treating fibrotic diseases and applications thereof |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CA2012311A1 (fr) | 1989-03-16 | 1990-09-16 | Max L. Birnstiel | Nouveau produit de conjugaison proteine-polycation |
WO1994002595A1 (fr) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif pour le traitement de maladies chez les animaux |
WO1995018863A1 (fr) | 1994-01-10 | 1995-07-13 | Rhone-Poulenc Rorer S.A. | Composition contenant des acides nucleiques, preparation et utilisations |
WO1995021931A1 (fr) | 1994-02-08 | 1995-08-17 | Rhone-Poulenc Rorer S.A. | Composition contenant des acides nucleiques, preparation et utilisations |
US5459127A (en) | 1990-04-19 | 1995-10-17 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1996017823A1 (fr) | 1994-12-05 | 1996-06-13 | Rhone-Poulenc Rorer S.A. | Lipopolyamines comme agents de transfection et leurs applications pharmaceutiques |
WO1996025508A1 (fr) | 1995-02-17 | 1996-08-22 | Rhone-Poulenc Rorer S.A. | Compositions contenant des acides nucleiques, preparation et utilisation |
US5580859A (en) | 1989-03-21 | 1996-12-03 | Vical Incorporated | Delivery of exogenous DNA sequences in a mammal |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US6277981B1 (en) | 1997-07-03 | 2001-08-21 | Thomas Jefferson University | Method for design and selection of efficacious antisense oligonucleotides |
US6416951B1 (en) | 1998-03-03 | 2002-07-09 | Brax Group Ltd. | Screening for functional antisense agents |
US6500615B1 (en) | 1996-10-04 | 2002-12-31 | Xzillion Gmbh & Co. | Identifying antisense oligonucleotide binding |
US20030180258A1 (en) | 2000-05-16 | 2003-09-25 | Van Es Helmuth Hendrikus Gerardus | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
US20040071660A1 (en) | 2000-09-26 | 2004-04-15 | Havenga Menzo Jans Emco | Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts |
WO2004094636A1 (fr) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Constructions demontables effectives d'arnsi |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69840568D1 (de) | 1997-04-14 | 2009-04-02 | Arena Pharm Inc | Methode zum identifizieren von modulatoren der zelloberflächenmembranrezeptoren,nützlich zur behandlung von krankheiten |
CA2406725C (fr) * | 2000-04-26 | 2013-01-15 | Aventis Pharma Deutschland Gmbh | Recepteur edg8, sa preparation et son utilisation |
DE10053879A1 (de) * | 2000-07-11 | 2002-02-07 | Margarete Odenthal | Genexpression, Genomalteration und Reporterexpression in Myofibroblasten und myofibroblast-ähnlichen Zellen |
AU2002246680A1 (en) * | 2000-12-22 | 2002-07-30 | University Of South Florida | Sphingosine 1-phosphate receptor gene, sppr |
US20020098998A1 (en) * | 2001-01-22 | 2002-07-25 | Marks Andrew R. | P27 prevents cellular migration |
US20060057559A1 (en) * | 2004-06-23 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | High-throughput cell migration screening assay |
US20090191578A1 (en) * | 2004-07-27 | 2009-07-30 | Merck & Co., Inc | Canis sphingosine 1-phosphate receptor isoform 5 |
CA2667706A1 (fr) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions et procedes pour traiter des maladies et des troubles oculaires |
US8114608B2 (en) * | 2006-11-30 | 2012-02-14 | University Of Virginia Patent Foundation | Methods for treating and diagnosing fibrotic and fibroproliferative diseases |
ES2656232T3 (es) * | 2009-05-08 | 2018-02-26 | Novartis Ag | Métodos de modulación de fibrosis usando moduladores de la proteína morfogenética ósea 9 (BMP-9) |
WO2011139846A2 (fr) * | 2010-04-28 | 2011-11-10 | Allegheny-Singer Research Institute | Compositions et méthodes pour réduire les cicatrices et traiter la fibrose |
EP2611908A4 (fr) * | 2010-09-01 | 2014-04-02 | Univ California | Criblage de culture cellulaire pour agents régulant l'adipogenèse et la différenciation myofribroplastique |
FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
-
2014
- 2014-03-07 JP JP2015562042A patent/JP2016518812A/ja active Pending
- 2014-03-07 EP EP14708866.0A patent/EP2972380A2/fr not_active Withdrawn
- 2014-03-07 WO PCT/EP2014/054442 patent/WO2014139884A2/fr active Application Filing
- 2014-03-07 US US14/775,828 patent/US9952202B2/en not_active Expired - Fee Related
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CA2012311A1 (fr) | 1989-03-16 | 1990-09-16 | Max L. Birnstiel | Nouveau produit de conjugaison proteine-polycation |
US5580859A (en) | 1989-03-21 | 1996-12-03 | Vical Incorporated | Delivery of exogenous DNA sequences in a mammal |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5589466A (en) | 1989-03-21 | 1996-12-31 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5459127A (en) | 1990-04-19 | 1995-10-17 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1994002595A1 (fr) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif pour le traitement de maladies chez les animaux |
WO1995018863A1 (fr) | 1994-01-10 | 1995-07-13 | Rhone-Poulenc Rorer S.A. | Composition contenant des acides nucleiques, preparation et utilisations |
WO1995021931A1 (fr) | 1994-02-08 | 1995-08-17 | Rhone-Poulenc Rorer S.A. | Composition contenant des acides nucleiques, preparation et utilisations |
WO1996017823A1 (fr) | 1994-12-05 | 1996-06-13 | Rhone-Poulenc Rorer S.A. | Lipopolyamines comme agents de transfection et leurs applications pharmaceutiques |
WO1996025508A1 (fr) | 1995-02-17 | 1996-08-22 | Rhone-Poulenc Rorer S.A. | Compositions contenant des acides nucleiques, preparation et utilisation |
US6500615B1 (en) | 1996-10-04 | 2002-12-31 | Xzillion Gmbh & Co. | Identifying antisense oligonucleotide binding |
US6277981B1 (en) | 1997-07-03 | 2001-08-21 | Thomas Jefferson University | Method for design and selection of efficacious antisense oligonucleotides |
US6416951B1 (en) | 1998-03-03 | 2002-07-09 | Brax Group Ltd. | Screening for functional antisense agents |
US20030180258A1 (en) | 2000-05-16 | 2003-09-25 | Van Es Helmuth Hendrikus Gerardus | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
US20040071660A1 (en) | 2000-09-26 | 2004-04-15 | Havenga Menzo Jans Emco | Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts |
US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
WO2004094636A1 (fr) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Constructions demontables effectives d'arnsi |
Non-Patent Citations (57)
Title |
---|
"Remington's Pharmaceutical Sciences", 1980 |
ADAMES ET AL., NATURE, vol. 318, 1985, pages 533 - 8 |
ALEXANDER ET AL., MOL. CELL. BIOL., vol. 7, 1987, pages 1436 - 44 |
AMBROS, NATURE, vol. 431, 2004, pages 350 - 355 |
BARREL, CELL, vol. 1, no. 16, 2004, pages 281 - 297 |
BETHANY B. MOORE; CORY M. HOGABOAM: "Murine models of pulmonary fibrosis", AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 294, 2008, pages L152 - L160 |
BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95 |
BOSTROM H; WILLETTS K; PEKNY M ET AL.: "PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis", CELL, vol. 85, 1996, pages 863 - 73 |
CHEN ET AL., NUCLEIC ACIDS RES., vol. 20, 1992, pages 4581 - 9 |
CHIANG ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 18162 - 18171 |
COLE: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77 |
CULLEN, VIRUS RESEARCH., vol. 102, 2004, pages 3 - 9 |
CURIEL ET AL., HUM. GENE THER., vol. 3, 1992, pages 147 - 54 |
EICKELBERG O; KOHLER E; REICHENBERGER F ET AL.: "Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-betal and TGF-beta3", AM J PHYSIOL, vol. 276, 1999, pages L814 - 24 |
FELGNER, PROC. NATL. ACAD SCI. USA, vol. 84, 1987, pages 7413 - 7 |
FELGNER; RINGOLD, NATURE, vol. 337, 1989, pages 387 - 8 |
GABBIANI G.: "The myofibroblast in wound healing and fibrocontractive diseases", J PATHOL., vol. 200, 2003, pages 500 - 3 |
GAO; HUANG, NUCLEIC ACIDS RES., vol. 21, 1993, pages 2867 - 72 |
GROSSCHEDL ET AL., CELL, vol. 38, 1984, pages 647 - 58 |
HE ET AL., NAT. REV. GENET., vol. 5, 2004, pages 522 - 531 |
HO ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 59 - 630 |
HO ET AL., NUCL ACIDS RES, vol. 24, 1996, pages 1901 - 1907 |
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381 - 8 |
KASHANI-SABET ET AL., ANTISENSE RES. DEV., vol. 2, 1992, pages 3 - 15 |
KOHAN M; PUXEDDU I; REICH R ET AL.: "Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts", ANN ALLERGY ASTHMA IMMUNOL, vol. 104, 2010, pages 66 - 72, XP026959068 |
KOLLIAS ET AL., CELL, vol. 46, 1986, pages 89 - 94 |
LEDER ET AL., CELL, vol. 45, 1986, pages 485 - 95 |
LIAO ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, 1997, pages 2969 - 2976 |
LIMA ET AL., BIOCHEM., vol. 31, 1992, pages 12055 - 12061 |
LIPINSKI CA; LOMBARDO F; DOMINY BW; FEENEY PJ: "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings", ADV. DRUG DELIV. REV., vol. 46, no. 1-3, March 2001 (2001-03-01), pages 3 - 26 |
MACKEY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 8027 - 31 |
MARK; PADLAN: "The Handbook of Experimental Pharmacology", vol. 113, 1994, SPRINGER-VERLAG, article "Chapter 4. Humanization of Monoclonal Antibodies" |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 97 |
MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537 - 9 |
MISHRA ET AL., LIFE SCIENCES, vol. 317, 1994, pages 977 - 982 |
MOGRAM ET AL., NATURE, vol. 315, 1985, pages 338 - 40 |
PIERCE EM; CARPENTER K; JAKUBZICK C ET AL.: "Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21", EUR RESPIR J, vol. 29, 2007, pages 1082 - 93 |
PUXEDDU I; BADER R; PILIPONSKY AM ET AL.: "The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts", J ALLERGY CLIN IMMUNOL, vol. 117, 2006, pages 103 - 10, XP005228132, DOI: doi:10.1016/j.jaci.2005.08.057 |
SCOTTON CJ; CHAMBERS RC: "Molecular targets in pulmonary fibrosis: the myofibroblast in focus", CHEST, vol. 132, 2007, pages 1311 - 21, XP009094953, DOI: doi:10.1378/chest.06-2568 |
SETHUPATHY ET AL., RNA, vol. 12, 2006, pages 192 - 197 |
SIDIROPOULOS ET AL., GENE THERAPY, vol. 8, 2001, pages 223 - 231 |
STARKEL P; LECLERCQ LA.: "Animal models for the study of hepatic fibrosis", BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, vol. 25, no. 2, 2011, pages 319 - 333, XP028191999, DOI: doi:10.1016/j.bpg.2011.02.004 |
STULL ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 3501 - 3508 |
TODD NW; LUZINA IG; ATAMAS SP, FIBROGENESIS MOLECULAR AND CELLULAR MECHANISMS OF PULMONARY FIBROSIS TISSUE REPAIR, vol. 5, 2012, pages 11 - 35 |
TRAUNEEKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 9 |
ULMER ET AL., SCIENCE, vol. 259, 1993, pages 1745 - 8 |
VENTURA ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 3249 - 55 |
WICKSTROM ET AL.: "Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS", 1991, WILEY-LISS, INC., pages: 7 - 24 |
WILLIAMS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 2726 - 30 |
WILSON ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 963 - 7 |
WU; WU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 32 |
WU; WU, J. BIOL. CHEM., vol. 263, 1988, pages 14621 - 4 |
WYNN TA.: "Cellular and molecular mechanisms of fibrosis", J PATHOL., vol. 214, 2008, pages 199 - 210, XP002553819, DOI: doi:10.1002/path.2277 |
WYNN TA.: "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases", J CLIN INVEST, vol. 117, 2007, pages 524 - 9, XP009137678 |
WYNN TA.: "Fibrotic disease and the T(H)1/T(H)2 paradigm", NAT REV IMMUNOL., vol. 4, 2004, pages 583 - 94, XP009070836, DOI: doi:10.1038/nri1412 |
YING, GENE, vol. 342, 2004, pages 25 - 28 |
ZEISBERG M; MARY A.; SOUBASAKOS, RAGHU KALLURI: "Animal Models of Renal Fibrosis. Fibrosis Research", METHODS IN MOLECULAR MEDICINE, vol. 117, 2005, pages 261 - 272 |
Also Published As
Publication number | Publication date |
---|---|
WO2014139884A3 (fr) | 2014-12-31 |
US9952202B2 (en) | 2018-04-24 |
EP2972380A2 (fr) | 2016-01-20 |
JP2016518812A (ja) | 2016-06-30 |
US20160069868A1 (en) | 2016-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10048250B2 (en) | Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases | |
EP2259063B1 (fr) | Analyses de criblage de composés permettant d'induire une différenciation de cellules mammaliennes non différenciés en ostéoblastes | |
US20110105587A1 (en) | Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases | |
WO2011015572A1 (fr) | Cibles et composés moléculaires, et procédés pour leur identification utiles dans le traitement de maladies neurodégénératives | |
US20160003808A1 (en) | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition | |
WO2011015573A1 (fr) | Cibles et composés moléculaires, et procédés pour les identifier, utiles dans le traitement de maladies neurodégénératives | |
JP2010538244A (ja) | 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法 | |
US20120004160A1 (en) | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation | |
US20110077283A1 (en) | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases | |
US9952202B2 (en) | Methods of identifying compounds for the treatment of fibrosis by using S1PR5 | |
US20140256790A1 (en) | Methods for Identifying and Compounds Useful for Increasing the Functional Activity and Cell Surface Expression of CF-Associated Mutant Cystic Fibrosis Transmembrance Conductance Regulator | |
WO2014082993A2 (fr) | Cibles moléculaires et composés, et procédés d'identification de ceux-ci, utiles dans la régulation à la baisse de la réponse th2 | |
US20110306655A1 (en) | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14708866 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2015562042 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14775828 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014708866 Country of ref document: EP |